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Herpes simplex virus (HSV) is a clinically important virus, whose life cycle
alternates between productive replication and latency. Infected cell protein 0
(ICP0) is generally believed to play a key role in determining the outcome of HSV
infections. Synthesis of ICP0 promotes the productive replication of HSV,
whereas absence of ICP0 renders HSV prone to establish latent infections.
In the first part of the dissertation, I attempt to address the question how is
ICP0 gene regulated. To tackle this question, we constructed recombinant HSV
that encodes GFP-tagged ICP0 so that the regulation of ICP0 gene can be
visualized in real time. Using this reagent, we found that ICP0 gene was subject
to potent repression immediately following infection. Surprisingly, HSV’s major
transcriptional regulator, ICP4, was necessary and sufficient to repress ICP0
gene, and did so in an ICP4-binding-site dependent manner. Synthesis of ICP0
i

alleviated the ICP4-dependent repression of ICP0 gene. ICP4 coimmunoprecipitated with FLAG-tagged ICP0, thus, a physical interaction between
ICP0 and ICP4 likely explains how ICP0 antagonizes ICP4’s capacity to silence
the ICP0 gene. Therefore, our findings suggest that ICP0 gene is differentially
regulated by virus-encoded repressor ICP4 and virus-encoded antirepressor
ICP0.
In the second part of the dissertation, I attempt to address the question
what function does ICP0 assume. Since the discovery of ICP0, the nuclear
function of ICP0 has been the focal point of studies, whereas the cytoplasmic
function of ICP0 is unknown. While pursuing our first study, we unexpectedly
found that GFP-tagged ICP0 was predominantly localized to the cytoplasm
during infections. Taking advantage of live-cell imaging, we found that ICP0
translocated from nucleus to cytoplasm during early phase of HSV infections,
where it bundled and dispersed microtubules. Synthesis of ICP0 was proved to
be necessary and sufficient to dismantle microtubules in HSV-infected and
transfected cells. Therefore, our findings suggest ICP0 might play a previously
unrecognized role in the cytoplasm through dismantling microtubule networks of
the host cells. Furthermore, our study represents the first report showing a virusencoded E3 ligase disrupts host cell microtubule networks, thus suggests a
general function of many other viral E3 ligases.
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CHAPTER1: INTRODUCTION

Herpes simplex virus (HSV) infection is a clinically important virus, which is
carried by 80% of the population in the world (1). Although there is only 2%
chance that a given HSV infection will progress into recurrent herpetic diseases,
the actual number of people suffering from herpetic disease is estimated to be
100 million due to the high prevalence of HSV (1).
HSV life cycle alternates between productive replication and latency.
Although the mechanisms by which HSV establishes, maintains and reactivates
from latency are not well understood, it is generally believed that ICP0 plays an
important role in the regulation of the balance between productive and latent
infections (2, 3). Synthesis of ICP0 tips the balance toward productive infection,
whereas absence of ICP0 tilts the balance toward latent infection (2, 3).
Therefore, it would be of extreme interest to understand the questions 1) how is
ICP0 gene regulated, and 2) what function does ICP0 assume during HSV
infection. The specific introduction to each question is detailed below:

1.1. GENE REGULATION OF ICP0
During productive replication, ~75 proteins are synthesized from the herpes
simplex virus (HSV) genome in a temporal cascade (4). Virion protein 16 (VP16)
in the tegument of HSV virions forms a complex with the cellular transcription
factor Oct 1 to initiate a cascade of viral gene expression (5, 6). Only five
1

immediate-early (IE) genes are initially induced based on the presence of VP16responsive elements in their promoters (7). Viral IE proteins such as infected cell
proteins 0 (ICP0) and 4 (ICP4) are believed to play a key role in activating viral
mRNA synthesis, and thus promoting the synthesis of ~70 early (E) and late (L)
proteins that replicate and package HSV genomes into new virions.
ICP0 was first identified based on its capacity to transform HSV’s major
transcriptional regulator, ICP4, from a weak transcriptional activator to a potent
activator of mRNA synthesis; specifically, combinations of ICP0 and ICP4 are 20fold more potent at driving mRNA synthesis than either ICP0 or ICP4 alone (8,
9). Functionally, synthesis of ICP0 causes HSV’s equilibrium to abruptly tip
towards productive replication, whereas absence of ICP0 produces the opposite
effect. Synthesis of ICP0 is sufficient to trigger HSV reactivation in trigeminal
ganglion neurons and other models of latent HSV infection (10, 11). HSV ICP0viruses replicate to nearly wild-type levels when cells are inoculated with more
than 1 plaque-forming unit (pfu) of virus per cell. At multiplicities of infection
(MOI) below 0.1 pfu per cell, the same ICP0- viruses establish quiescent
infections in 99% of the cells they infect (12, 13). Such observations suggest that
ICP0 antagonizes a repressor of HSV replication, whose repressive capacity can
be saturated with high numbers of HSV genomes (13).
Preston and Everett first articulated the concept of an ICP0-antagonized
repressor of HSV gene expression (3, 14). Because ICP0 is an E3 ubiquitin
ligase (15), it was suggested that a repressor might silence HSV mRNA
synthesis in the absence of ICP0, whereas synthesis of ICP0 would result in
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ubiquitination and/or proteasomal destruction of the repressor, thus allowing HSV
mRNA synthesis to proceed unhindered (16). Since the advancement of this
hypothesis, many laboratories have joined in the search for the unidentified
repressor(s) of HSV gene expression. Individual cellular proteins that co-localize
with ICP0 have been probed for their capacity to function as repressors of HSV
replication such as PML and Sp100 (17, 18). Suspected pathways of silencing
HSV genomes, such as epigenetic silencing, have been explored to determine if
HSV ICP0- null viruses are more sensitive to these gene silencing mechanisms
(19-22). Based on such inquiries, the list of proteins that may function as ICP0antagonized repressors of HSV gene expression continues to grow and currently
includes PML (17-19, 23), Sp100 (24), cyclin D3 (25), IRF-3 and IRF-7 (26),
centromeric proteins CENP-B and CENP-C (27, 28), HDAC1/2-CoREST-REST
(19), DNA-dependent protein kinase (29), and class II histone deacetylases (22).
The PML protein is among the most carefully scrutinized of the potential
ICP0-antagonized repressors of HSV replication. In support of the PML
repressor hypothesis, ICP0 and HSV genomes co-localize with PML nuclear
bodies in cells (30, 31), synthesis of ICP0 triggers the dispersal of PML nuclear
bodies (30), and PML is strongly induced by interferon treatments that are known
to impede HSV replication (32). Weaknesses in the PML repressor hypothesis
include the fact that overexpression of PML does not inhibit HSV gene
expression and does not interfere with the replication of wild-type HSV or ICP0null viruses (33); unpublished data of W. Halford]. Although siRNA-knockdown of
both PML and Sp100 results in an ~40-fold increase in the replication of HSV
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ICP0- null viruses in human fibroblasts, this represents less than a 1%
complementation of the >10,000-fold repression that occurs in these cells (18).
Finally, there is no direct evidence of a physical interaction between ICP0 and
PML (34).
Like many laboratories, we too have been interested in understanding why
failure to synthesize ICP0 results in limited mRNA transcription from the HSV
genome. Rather than interrogate specific proteins for their capacity to repress
viral mRNA synthesis, we chose to establish an experimental system that would
allow us to rapidly monitor repression of a single HSV IE gene, the ICP0 gene.
To this end, an ICP0- virus was constructed that bore an ~750 bp insertion of
green fluorescent protein (GFP) coding sequence and a stop codon in exon 2 of
the ICP0 gene. The resulting virus, HSV-1 0-GFP, synthesized a 3.5 kb ICP0-GFP
mRNA and a truncated ICP0-GFP peptide. Using the GFP fluorescent reporter as
a screening tool, we probed for conditions that alleviated or exacerbated
repression of the ICP0-GFP reporter gene in HSV-infected cells such as presence
or absence of biologically active ICP0.
With the aid of these new reagents, we report the identification of a protein
that satisfied four empirical criteria that should be expected of an ICP0antagonized repressor of HSV mRNA transcription; specifically, the identified
protein 1. was required to observe repression of ICP0 mRNA synthesis in HSVinfected cells; 2. was sufficient to repress ICP0 mRNA synthesis in the absence
of ICP0; 3. was unable to silence ICP0 mRNA synthesis when ICP0
accumulated; and 4. physically interacted with ICP0.
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We report the unexpected finding that the viral IE protein, ICP4, satisfied all
of the criteria expected of a bona fide ICP0-antagonized repressor of HSV mRNA
transcription. It is relevant to note that ICP4’s capacity to function as a repressor
of HSV IE mRNA transcription is well established, particularly in the context of
the ICP4 and L/ST genes (35, 36). Evidence has been presented both for and
against the hypothesis that ICP4 represses the ICP0 gene in HSV-infected cells
(37, 38). However, the perceived importance of the hypothesis may be
measured in terms of the attention it has received; 14 years have elapsed since
the last published study that considered ICP4’s potential to repress the ICP0
gene (38).
We present new evidence that corroborates earlier findings that ICP4’s
capacity to repress ICP0 mRNA synthesis is indeed modest when ICP0
accumulates. However, when ICP0 fails to accumulate, then ICP4 is capable of
silencing the ICP0 gene. We present functional evidence that ICP0 antagonizes
ICP4-dependent repression of the ICP0 gene. In addition, we present the first
direct evidence that ICP0 and ICP4 physically interact in HSV-infected cells.
Collectively, these data suggest an alternative view of HSV gene regulation,
which is consistent with the biology of a virus that establishes latent infections: In
the absence of ICP0, ICP4 functions as an efficient repressor of HSV IE mRNA
transcription, whereas accumulation of ICP4’s binding partner, ICP0, converts
ICP4 from a repressor to an activator of HSV mRNA synthesis (8, 9). The
findings that led us to these unexpected conclusions are presented below.

5

1.2. FUNCTION OF ICP0
ICP0’s mechanism of action is unknown, but the possibilities are
constrained by four facts: 1. ICP0 potentiates ICP4’s function as a transcriptional
activator of HSV mRNA synthesis (8, 9, 39); 2. ICP0 is a RING-finger E3
ubiquitin ligase (15, 40); 3. ICP0 is essential for HSV’s resistance to the innate
interferon response of animals (2, 41); and 4. ICP0’s E3 ubiquitin ligase activity
triggers the dispersal of pro-myelocytic leukemia (PML) nuclear bodies (30, 42),
which may contribute to the formation of adjacent, sub-nuclear replication
compartments (43, 44).
Point mutations in ICP0’s RING-finger domain (amino acids 116 to 156)
destroy ICP0’s E3 ligase activity and destroy ICP0’s capacity to promote HSV
replication (40). It remains unclear which substrate(s) explain how ICP0’s E3
ligase activity promotes HSV replication and spread. Although ICP0 triggers the
efficient dispersal of PML nuclear bodies, ICP0 does not ubiquitinate the PML
protein in an in vitro E3 ligase assay (45).
In the first part of the dissertation, we clarifies that ICP0 physically interacts
with HSV’s major transcriptional regulator, ICP4, and suggests that ICP0
influences whether ICP4 functions predominantly as an activator or a repressor
of HSV mRNA synthesis (39). However, ICP0’s interaction with ICP4 does not
explain 1. how ICP0 triggers the dispersal of PML nuclear bodies and centromere
proteins (27, 42), nor does it explain 2. why synthesis of ICP0 causes cells to
arrest in the G2/M phase of the cell cycle (46, 47). These latter observations
suggest that ICP0 must interact with at least one cellular protein. Rather than
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interrogate specific proteins for their capacity to interact with ICP0, we chose to
use live-cell imaging to determine if new clues might be obtained by tracking the
distribution of a green fluorescent protein (GFP)-tagged form of ICP0 in HSVinfected cells over time.
Three ICP0+ viruses were constructed that bore an ~750 bp insertion of
GFP coding sequence inserted in the ICP0 gene. The resulting recombinant
viruses, HSV-1 0+GFP12, HSV-1 0+GFP24, and HSV-1 0+GFP105 each
synthesized a 3.5 kb ICP0+GFP mRNA and a 140 kDa protein. Each GFP-tagged
ICP0 protein retained much of ICP0’s activity, and was visible in HSV-1 infected
cells by fluorescent microscopy. Contrary to our initial expectations, the majority
of GFP-tagged ICP0 was observed in the cytoplasm of HSV-1 infected cells.
Subsequent tests verified that wild-type ICP0 also accumulated to much higher
levels in the cytoplasm than in the nucleus of virus-infected cells.
Since the discovery that ICP0 potently stimulates HSV mRNA synthesis (8,
9), sporadic reports have documented the presence of ICP0 in the cytoplasm of
HSV-infected cells, or have described ICP0 translocating from the nucleus to the
cytoplasm of HSV-infected cells (48-52). The biological significance of
cytoplasmic ICP0 remains obscure, and it remains possible that cytoplasmic
ICP0 represents an artifact of ICP0 overexpression (48, 49). Therefore, ICP0
continues to be discussed predominantly in terms of its potential function(s) in
the nucleus of HSV-infected cells (17, 27, 53, 54).
The results of the current study clarify that ICP0 is an exclusively nuclear
protein during the IE phase of HSV infection, but translocates to the cytoplasm
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during the early (E) phase. Once in the cytoplasm of HSV-infected cells, ICP0
efficiently bundles and disperses host cell microtubules. Microtubule networks
are known to be disrupted in HSV-infected cells (55), but the effectors that
mediate this process are unknown. The HSV-1 tegument protein VP22 bundles
microtubules when overexpressed in transfected cells (56), but this is not
observed in HSV-infected cells (57). Our results demonstrate that ICP0 is
necessary and sufficient to trigger the complete disassembly of the host cell
microtubule network. This finding adds to a growing list of proteins encoded by
plant and animal viruses that reorganize microtubules (58-61).
This is the first report of a viral E3 ligase that regulates microtubule stability.
Intriguingly, cellular E3 ligases such as the anaphase-promoting complex and
cullin 3 orchestrate massive reorganizations of microtubules during mitosis (6264). ICP0-like E3 ligases are not unique to herpes simplex virus, but are
encoded by at least 20 other α-herpesviruses that infect primates, dogs, pigs,
frogs, fish, and other species (65, 66). Thus, our results raise the possibility that
an ancestral herpesvirus may have stolen an E3 ligase from its host cell, and
modified this regulator of microtubule stability to suit the needs of the virus.
Specifically, our results imply that ICP0 possesses a mitosis-related regulatory
activity that disassembles microtubules upon ICP0’s translocation to the
cytoplasm, and hence prepares the host cell for the synthesis and/or egress of
newly formed HSV virions.
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CHAPTER 2: MATERIALS AND METHODS

2.1. CELLS AND VIRUSES
Vero cells and 293 cells were obtained from the American Type Culture
Collection (Manassas, VA). ICP4-complementing E5 and ICP0-complementing
L7 cell lines were kindly provided by Neal Deluca (University of Pittsburgh; (67)).
ICP27-complementing V27 cells and HSV-1 d27-1 (ICP27-) virus were a kind gift
of Steve Rice (University of Minnesota Medical School, Minneapolis; Ref. (68)).
Cell lines were propagated in Dulbecco’s Modified Eagle’s medium (DMEM)
supplemented with 5% fetal bovine serum and antibiotics.
Table 1 summarizes the HSV-1 recombinant viruses used in this study,
which are derivative of low passage strains of wild-type HSV-1 strain KOS (69).
HSV-1 KOS, HSV-1 22/n199 (ICP22-; Ref. (70)), HSV-1 0+GFP12 (ICP0+GFP-12),
HSV-1 0+GFP24 (ICP0+GFP-24), HSV-1 0+GFP105 (ICP0+GFP-105) and HSV-1 0+4BS(ICP0+GFP-105) were propagated in Vero cells. The HSV-1 ICP4- virus n12 (71)
and the ICP4 temperature-sensitive virus HSV-1 tsB21 (72) were propagated in
ICP4-complementing E5 cells. The HSV-1 ICP0- viruses n212 (73), 0-GFP
(ICP0-GFP), 0-4BS- (ICP0-GFP) and 0(∆RING) (ICP0∆RING) were propagated and
titered in ICP0-complementing L7 cells, as was the HSV-1 VP16- virus RP4 (74)
that was kindly provided by Steve Triezenberg (Michigan State University, East
Lansing).
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HSV-1 strain KOS was used as the parental wild-type virus in this study.
KOS and all of the HSV-1 recombinant viruses used in this study were
propagated in Vero cells, L7 cells, or E5 cells cultured in complete DMEM. KOSGFP is a recombinant virus derived from HSV-1 strain KOS that expresses GFP
from a CMV promoter cassette inserted in the intergenic region at the 3' ends of
the UL26 and UL27 genes (75, 76). To construct HSV-1 recombinant viruses, a
7.3 kb DNA fragment which encompasses the entire LAT-ICP0 locus was first
subcloned from HSV-1 strain KOS into a pCRII plasmid vector (Invitrogen
Corporation, Carlsbad, CA). Mutations were introduced into the ICP0 gene of
this plasmid, as described below.
i. p0+GFP12: A GFP coding sequence was amplified from plasmid
peGFP-N1 (Clontech Laboratories, Mountain View, CA) using PCR primers that
added NcoI and Bsu36I restriction sites to the 5’ and 3’ ends of the GFP coding
sequence. Following PCR amplification with a high fidelity mixture of
thermostable DNA polymerases, the GFP sequence was subcloned into NcoI
and Bsu36I sites that occur in codons 1 and 11 of the ICP0 coding sequence.
The resulting plasmid, p0+GFP12, encoded ICP0+GFP-12 protein. The genetic
identity of this and all GFP insertions in the ICP0 gene was confirmed by DNA
sequencing. Homologous recombination between HSV-1 KOS and the p0+GFP12
plasmid yielded the recombinant virus HSV-1 0+GFP12.
ii. p0+GFP24: The plasmid p0+GFP24 was created by PCR amplification of
three DNA fragments that were ligated in series to create a GFP insertion at the
5’ end of exon 2 of the ICP0 gene (Fig. 1A). Specifically, 1. the 3’ end of intron 1
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of the ICP0 gene; 2. a GFP coding sequence; and 3. the 5’ half of exon 2 of the
ICP0 gene were PCR-amplified, ligated together, sequenced, and the resulting
BamHI - XhoI fragment was subcloned into the BamHI - XhoI sites in the ICP0
gene. The resulting plasmid, p0+GFP24, encoded ICP0+GFP-24 protein in which
GFP is inserted between amino acids 23 and 24 of ICP0. Homologous
recombination between HSV-1 KOS and the p0+GFP24 plasmid yielded the
recombinant virus HSV-1 0+GFP24.
iii. p0-GFP: The plasmid p0-GFP gene was created by inserting a
polylinker, GFP coding sequence, and stop codon derived from the plasmid
peGFP-N1 (Clontech Laboratories) into a XhoI site in codon 104 of the ICP0
gene. The resulting plasmid, p0-GFP, encoded the N-terminal 104 amino acids
of ICP0, a 14 amino acid linker, and GFP. Homologous recombination between
HSV-1 KOS and the p0-GFP plasmid yielded the recombinant virus HSV-1 0GFP.
iv. p0+GFP105: The plasmid p0+GFP105 was derived by subcloning a
dsDNA linker containing BsrGI and XhoI sites (tgtaca agatat ctcgag) in the 3’ end
of the GFP coding sequence in p0-GFP. Thus, a TAA terminator codon was
removed and the GFP and ICP0 coding sequences were placed in the same
open-reading frame. The resulting plasmid, p0+GFP105, encoded ICP0+GFP-105
protein in which GFP is inserted between amino acids 104 and 105 of ICP0.
Homologous recombination between HSV-1 KOS and p0+GFP105 yielded the
virus HSV-1 0+GFP105.
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v. p0∆RING: The plasmid p0∆RING was derived by deletion of codons
105-229 of the ICP0 gene from p0+GFP105. Homologous recombination between
HSV-1 KOS and the p0∆RING plasmid yielded the recombinant virus HSV-1
0∆RING.
vi. p0-4BS- and p0+4BS-: The plasmids p0-4BS- and p0+4BS- were
created as follows. A plasmid, pmin0-GFP, contains the ICP0 promoter region
and a unique TfiI restriction site that overlaps the ICP4 DNA-binding site (4BS)
element in the ICP0 promoter. Thus, mutation of the 4BS element was achieved
by linearizing pmin0-GFP with TfiI, using mung bean exonuclease to remove
ssDNA overhangs, and religating with T4 DNA ligase. The 4-bp deletion in the
4BS element was confirmed by the loss of the TfiI restriction site and DNA
sequencing (Figure 1A). The ICP4-binding site mutation was transferred into the
larger plasmids p0-GFP and p0+GFP105 by subcloning a XhoI - EcoRI restriction
fragment to yield the plasmids p0-4BS- and p0+4BS-. Homologous recombination
between HSV-1 KOS and these plasmids yielded the HSV-1 recombinant viruses
0-4BS- and 0+4BS- (Table 1).
vii. p0+FLAG24: The plasmid p0+FLAG24 was created as follows. A
plasmid, p0+GFP24, contained a BglII restriction site-GFP coding sequence-SpeI
restriction site insertion between amino acids 23 and 24 of the ICP0 openreading frame. A dsDNA oligonucleotide linker of the following sequence was
synthesized, CCCAGATCTGGACTACAAGGACGATGACGACAAACTAGTCTG,
digested with BglII and SpeI, and subcloned in place of the GFP sequence to
create p0+FLAG24. The resulting gene encoded a FLAG-tagged protein that bore
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the amino acid sequence LDYKDDDDKL between amino acids 23 and 24 of
ICP0. Homologous recombination between HSV-1 KOS and p0+FLAG24 yielded
the HSV-1 recombinant virus 0+FLAG24 (Table 1).
Table 2 summarizes the ΔE1-ΔE3 adenovirus vectors used in this study,
which were propagated in human embryonic kidney 293 cells in complete DMEM,
as described previously (10). Adenovirus titers were determined by a limiting
dilution analysis in 96-well cultures of 293 cells to establish the titer of infectious
virus in terms of 50% tissue-culture infectious dose (TCID50). One TCID50 unit is
equivalent to 1 pfu, but the TCID50 assay is less prone to underestimate
adenovirus vector titers (unpublished data).

2.2. CONSTRUCTION OF RECOMBINANT HSV-1 VIRUSES
Infectious HSV-1 DNA was prepared by a protocol that relies upon dialysis
to minimize shearing of genome-length HSV-1 DNA; this is a modification of a
protocol that was generously provided by Karen Mossman (McMaster University,
Hamilton, Ontario). Five 100 mm dishes of Vero cells (3x107 cells) were
inoculated with 5 pfu per cell of HSV-1 strain KOS. After 24 hours, cells were
scraped, centrifuged, rinsed with PBS, resuspended in 7.0 ml of 200 mM EDTA
pH 8.0, and transferred into a 15 ml conical. Proteinase K (75 µl of 10 mg/ml)
and 375 µl of 10% SDS were added to virus-infected cells, and the tube was
incubated in a rotisserie oven with slow rotation at 50ºC for 16 hours. Proteins
were removed by phenol : chloroform extraction, and DNA was transferred into a
0.5 – 3.0 mL Slide-a-lyzer cassette (10,000 MW cutoff; Pierce Chemical Co.,
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Rockford, IL) and dialyzed against 0.1x standard saline citrate for 24 hours.
Following dialysis, infectious HSV-1 DNA was aliquoted and frozen at -80ºC.
Recombinant HSV-1 viruses were generated by co-transfection of 2 µg
infectious HSV-1 KOS DNA and 1 µg each plasmid into a 60 mm dish containing
8 x 105 ICP0-complementing L7 cells. After 12 hours, medium was replaced with
complete DMEM containing 1% methylcellulose and GFP+ plaques were selected
on a Nikon TE2000 fluorescent microscope (Nikon Instruments, Lewisville, TX).
GFP+ recombinant viruses were repeatedly passed in ICP0-complementing L7
cells until a uniform population of viruses was obtained that produced 100%
GFP+ plaques, at which time Southern blot analysis was used to confirm that the
anticipated mutation had been introduced into the ICP0 gene of HSV-1.

2.3. SOUTHERN BLOT ANALYSIS
Vero cell cultures were established at a density of 1.5 x 106 cells per 100
mm dish and were inoculated with viruses at an MOI of 5 pfu per cell. DNA was
harvested from virus-infected cells or uninfected controls at 24 hours p.i. using a
standard DNA extraction procedure and Southern blot analysis was performed as
previously described (77, 78). Oligonucleotide probes specific for intron 1 of the
ICP0 gene (5’-cccctagatgcgtgtgagtaaggggggcctgcgtatgagt-3’) were used to
probe restriction fragments of HSV-1 viruses.

14

2.4. NORTHERN BLOT ANALYSIS
Cultures of L7 or Vero cells were established at a density of 1.5 x 106 cells
per plate in 60 mm dishes, and inoculated with MOIs of 0.1 to 5 pfu per cell.
RNA was isolated using Ultraspec RNA isolation reagent (Biotecx Inc., Houston,
TX). Equal amounts of total RNA (10 μg) were electrophoretically separated on
1% formaldehyde agarose gels, blotted onto Zeta Probe GT nylon membranes
(Biorad Laboratories, Hercules, CA), and hybridized with radiolabeled
oligonucleotides specific for exon 3 of HSV-1 ICP0 mRNA (5'-ggagtcgctgatcactatggggtctctgttgtttgcaagg-3'), GFP mRNA (5’-atagacgttgtggctgttgtagttgtactccagcttgtgc-3′), HSV-1 glycoprotein D mRNA (5'-aggcccccagagacttgttgtaggagcattcggtgtactc-3') or cellular GAPDH mRNA (5'-tgaccttggccaggggtgctaagcagttggtggtgcagga-3'). Oligonucleotides were end-labeled with [α-32P] dATP
using terminal deoxynucleotidyl transferase (Promega Corporation, Madison, WI)
and were hybridized to their target sequence via 16 hours of hybridization at
37°C in a solution containing 5 ng/ml labeled probe, 7% SDS, 120mM NaH2PO4,
and 250mM NaCl. Excess probe was removed from membranes by sequential
rinses in 0.1x standard saline citrate containing 0.1% SDS. Blots were exposed
to phosphor screens, which were scanned and analyzed with a Cyclone
PhosphorImager and OptiQuant software (Perkin Elmer, Boston, MA).
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2.5. WESTERN BLOT ANALYSIS
Vero cell cultures were established at a density of 3 x 105 cells per well in
12-well plates, and were infected at an MOI of 10 pfu per cell. After 18 hours,
proteins were harvested using mammalian protein extraction reagent (Pierce
Chemical Co., Rockford, IL) supplemented with 1 mM dithiothreitol and protease
inhibitor cocktail set I (Calbiochem, La Jolla, CA). After heat denaturation, 20 μg
of each protein sample and MagicMarkTM XP protein MW markers (Invitrogen
Corporation, Carlsbad, CA) were resolved in a 10% polyacrylamide gel with a 4
% stacking gel, and were transferred to nitrocellulose membranes. Protein blots
were blocked in phosphate-buffered saline (PBS) containing 5% nonfat dry milk,
and were incubated overnight at 4°C in PBS + 0.1% Tween-20 + 5% nonfat dry
milk containing a 1:1000 dilution of mouse monoclonal H1083 antibody specific
for amino acids 395 to 775 of ICP0 (79-81) (EastCoast Bio, North Berwick, MA)
and a 1:500 dilution of rabbit polyclonal anti-GFP antibody (Clontech
Laboratories Inc.). Following incubation with primary antibodies, membranes
were washed four times with PBS + 0.1% Tween-20 (PBS-T), and were
incubated for 1 hour with 1:20,000 dilution of goat anti-rabbit IgG and goat antimouse IgG conjugated, respectively, to the infrared fluorescent dyes IRDye® 680
and IRDye® 800CW (LI-COR Bioscience, Lincoln, NE). Protein blots were
washed three times in PBS-T, and were scanned for two-color fluorescence
using the Odyssey Infrared imaging system (LI-COR Bioscience). Data were
analyzed using Odyssey application software version 3.0.16 (LI-COR
Bioscience).
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2.6. IMMUNOFLUORESCENT STAINING IN VERO CELLS
Immunofluorescent staining in Vero cells was performed using an
adaptation of a staining protocol that was generously provided by Roger Everett
(MRC Virology Unit, Glasgow, Scotland). Glass coverslips were placed on the
bottom of 6-well dishes and Vero cells were seeded at a density of 1 x 106 cells
per well. After allowing 8 hours for cell attachment, cultures were inoculated with
HSV-1 viruses using the conditions defined in each Figure Legend and Results
sub-section. At the indicated time of harvest, glass coverslips were removed
from culture wells, and were fixed with PBS containing 3% formaldehyde and 2%
sucrose for 10 minutes, followed by permeabilization with 90% methanol for 10
minutes. HSV-1 Fc-γ receptors (glycoprotein E-I heterodimers; Ref. (82)) were
blocked along with all other non-specific protein-binding sites by incubating fixed
cells in a solution of PBS containing 0.5% fetal bovine serum (FBS), as well as
10 µg / ml each of the γ-globulin fractions of human, donkey, and goat serum
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). Fixed cells
were incubated in PBS + FBS + γ-globulin block solution for 10 minutes, and the
same solution was used as the diluent for primary and secondary antibodies.
Each protein of interest was labeled by incubating fixed cells in a 1:1000 dilution
of primary antibody for 16 hours. Excess primary antibody was removed by
washing with PBS + FBS + γ-globulin block solution, and cells were then
incubated for 1 hour in PBS + FBS + γ-globulin block containing a 1:1000 dilution
of each secondary antibody as well as 10 ng / ml of Hoechst 33342 (Calbiochem,
La Jolla, CA). Excess secondary antibody was removed by washing with the
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PBS + FBS + γ-globulin block solution, and coverslips were mounted on glass
slides using FluorSave Reagent (Calbiochem, Gibbstown, NJ). Cells on
coverslips were photographed using an Olympus BX41 microscope equipped
with Olympus DP70 digital camera (Olympus America, Center Valley, PA).
Images of green, red, and blue fluorescence were captured at exposure times of
500, 200, and 20 ms, respectively.
The primary antibodies were mouse α-ICP0 monoclonal antibody H1083
(EastCoast Bio), mouse anti-FLAG monoclonal antibody (Sigma Chemical Co.),
rabbit anti-α-tubulin polyclonal antibody ab18251 (Abcam, Cambridge, MA),
rabbit anti-β-COP polyclonal antibody ab2899 (Abcam, Cambridge, MA), rabbit
anti-calreticulin polyclonal antibody ab4 (Abcam, Cambridge, MA). The
secondary antibodies were Alexa Fluor 594-conjugated goat α-mouse IgG
(Molecular Probes, Eugene, OR), fluorescein-conjugated goat α-mouse IgG
(Jackson ImmunoResearch), or DyLight 594-conjugated donkey α-rabbit IgG
(Jackson ImmunoResearch).

2.7. CO-IMMUNOPRECIPITATION
Replicate 100 mm dishes containing 107 Vero cells were inoculated with
vehicle or 5 pfu per cell of HSV-1 KOS or HSV-1 0+FLAG24 in the presence of
200 µM cycloheximide. At 10 hours p.i., cycloheximide-containing medium was
replaced with 10 µg/ml actinomycin D, and 6 hours was allowed for translation of
accumulated IE mRNAs. At 16 hours p.i., 100 mm dishes of Vero cells were
washed with ice-cold phosphate-buffered saline, and cells were lysed in either
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0.5 ml of an NP40-based buffer or RIPA buffer. The NP40-based buffer
contained 50 mM Tris (pH 7.4), 150 mM sodium chloride, 2 mM EDTA, 1%
NP40, and 1x Halt protease inhibitor cocktail (Pierce Chemical Co.). RIPA buffer
consisted of 50 mM Tris (pH 8.0), 150 mM sodium chloride, 1% NP40, 0.5%
sodium deoxycholate, 0.1% SDS, and 1x Halt protease inhibitor cocktail. Cell
lysed for 2 hours at 4ºC on a rotisserie, cell debris was removed by
centrifugation, and 10% of each lysate was reserved for Western blot comparison
of relative levels of ICP0 and ICP4. Supernatants were pre-cleared by incubation
with 1 μg normal mouse IgG and Protein A/G agarose beads (SantaCruz
Biotechnology) for 30 min at 4ºC. Pre-cleared supernatants were incubated with
15 μl of FLAG-M2 agarose beads (Sigma Chemical Company) overnight at 4ºC.
Immunocomplexes were washed four times with NP-40 buffer containing 500 mM
NaCl or RIPA buffer, and were prepared for Western blot analysis by boiling in 2x
Laemmli loading buffer prior to electrophoresis on an 8% polyacrylamide gel.
Transfer and detection of blotted proteins on PVDF membranes was performed
as described above.

2.8. TRANSFECTION OF VERO CELLS
Vero cells were transfected with plasmid DNA (0.75μg / well in 12-well
plates) using Lipofectamine 2000 (Invitrogen Corporation, Carlsbad, CA) in
complete DMEM at 37°C. Medium was replaced at 4 hours post-transfection to
avoid toxicity associated with the transfection reagent, and cells were incubated
at 37°C in complete DMEM until cells were fixed for immunofluorescent staining.
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Table 1
Description of HSV-1 viruses
Virus /
Genotype
KOS (wildtype)
-

Phenotype / Properties

Reference

Wild-type laboratory strain of HSV-1 (12 passages removed from isolation).

(69)

n212 (ICP0

Replicates with 1% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes the first

null)

211 of 775 amino acids of ICP0.

-

0 GFP

Replicates with 1% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes the first

-

(ICP0 null)
-

0 4BS

104 amino acids of ICP0 coupled to GFP.

-

(ICP0 null)
+

0 GFP12

104 amino acids of ICP0 coupled to GFP. A 4-bp deletion disrupts the ICP4 DNA-

length ICP0 with GFP in lieu of the first 11 amino acids.

+

0 GFP24

Replicates with 66% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes full-

+

(ICP0 )

length ICP0 with GFP inserted between amino acids 23 and 24.

+

0 GFP105

Replicates with 66% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes full-

+

(ICP0 )

length ICP0 with GFP inserted between amino acids 104 and 105.

0∆RING

Replicates with 1% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes ICP0

-

(ICP0 null)

with GFP in lieu of amino acids 105 and 229.

this study

this study

this study

this study

Replicates with 66% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes full-

-

length ICP0 with GFP inserted between amino acids 104 and 105. A 4-bp deletion

+

(ICP0 )

this study

disrupts the ICP4 DNA-binding site in the ICP0 promoter.

+

0 FLAG24

Replicates with 100% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes full-

+

(ICP0 )

length ICP0 with FLAG epitope inserted between amino acids 23 and 24.

RP4 (VP16

-

null)

Replicates with 1% efficiency at MOIs <0.1 pfu per cell; virus synthesizes VP16 protein
lacking half of the acidic transactivation domain (Δa.a. 413-454 [of 490]).

-

n12 (ICP4

Incapable of replication unless ICP4 is provided in trans; virus synthesizes the first 252

null)

of 1298 amino acids of ICP4.

tsB21

Replication-competent at 34º; replication-defective at 39.5º C; virus synthesizes a

ts

(ICP4 )

temperature-sensitive ICP4 protein (lesion maps to the C-terminal third).

d27-1

Incapable of replication unless ICP27 is provided in trans; virus bears a 1.6 kb deletion

-

(ICP27 null)

that removes 80% of the ICP27 ORF.

22/n199

Virus replicates like wild-type in cell culture but fails to replicate in animals; virus

-

this study

binding site in the ICP0 promoter.
Replicates with 66% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes full-

+

(ICP0 )

+

this study

Replicates with 1% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes the first

-

0 4BS

(73)

(ICP22 null)

synthesizes the first 198 of 420 amino acids of ICP22.
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this study

(74)

(83)

(72)

(68)

(70)

Table 2
Description of ∆E1-E3 adenovirus vectors
Virus

Promoter / Gene product

Reference

Ad-null

TRE promoter / no gene product

(10)

Ad-ICP0

TRE promoter / wild-type ICP0 (775 amino acids)

(10)

TRE promoter / N-terminus of ICP0 (211 of 775 amino
Ad-n212

(10)
acids)

Ad-ICP4

TRE promoter / wild-type ICP4 (1298 amino acids)

(10)

Ad.CMV-TetOn

CMV promoter / TetOn (rtTA) protein

(10)
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CHAPTER 3: RESULTS

3.1. GENE REGULATION OF ICP0

3.1.1. Characterization of HSV viruses that express GFP-tagged ICP0
Three ICP0+GFP genes were constructed that encoded GFP-tagged ICP0
in which i. GFP replaced amino acids 1 to 11 of the 775-amino acid ICP0 protein
(ICP0+GFP-12); ii. GFP was inserted between amino acids 23 and 24 of ICP0
(ICP0+GFP-24); or iii. GFP was inserted between amino acids 104 and 105 of ICP0
(ICP0+GFP-105) (Fig. 1A). An ICP0-null control gene, the ICP0-GFP gene, encoded
only the N-terminal 104 amino acids of ICP0 fused to GFP (Fig. 1A). Chimeric
ICP0GFP genes were introduced into the LAT-ICP0 locus of HSV-1 strain KOS by
homologous recombination to yield HSV-1 0-GFP, 0+GFP12, 0+GFP24, or
0+GFP105 (Fig. 1B). Northern blot analysis verified that each of these viruses
synthesized the predicted 3.5 kb ICP0GFP mRNA (Fig. 1C). GFP-tagged ICP0
proteins were analyzed by two-color Western blot analysis. In cells infected with
wild-type HSV-1 KOS or KOS-GFP, ICP0-specific monoclonal antibody H1083
labeled the 110 kDa ICP0 protein (red band in Fig. 1D). In addition, the GFPexpressing recombinant virus, KOS-GFP (75), also encoded an ~30 kDa GFP
protein that was labeled by rabbit anti-GFP antibody (green band in Fig. 1D).
HSV-1 0-GFP encoded a truncated ~55 kDa protein that was only labeled by the
GFP-specific antibody, whereas the 0+GFP viruses encoded ~140 kDa ICP0+GFP22

12, -24, and -105

proteins that were labeled with both ICP0- and GFP-specific

antibodies (yellow bands in Fig. 1D).
The functionality of ICP0+GFP-12, -24, and -105 proteins was compared to ICP0.
Wild-type HSV-1 formed plaques with 100% efficiency in Vero cells relative to the
number of plaques that formed in ICP0-complementing L7 cells (Fig. 1E). In
contrast, only ~1% of HSV-1 0-GFP (ICP0-) viruses formed plaques in Vero cells
(Fig. 1E). Each HSV-1 0+GFP virus formed plaques in Vero cells at ~66%
efficiency relative to the number of plaques that formed in ICP0-complementing
L7 cells (Fig. 1E). Thus, ICP0+GFP-12, -24, or -105 protein each retained sufficient
activity to promote HSV-1 plaque formation with 45-fold greater efficiency than
the ICP0- null control virus, HSV-1 0-GFP.
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Figure 1
Characterization of HSV-1 viruses that express GFP-tagged ICP0.
(A) Schematic of the wild-type or chimeric ICP0 genes in wild-type HSV-1 strain
KOS or the recombinant viruses, HSV-1 0+GFP12, 0+GFP24, and 0+GFP105, and 0GFP. (B) Southern blot analysis of the ICP0 locus of HSV-1 KOS versus HSV-1
recombinant viruses based on hybridization of an ICP0 intron1-specific probe to
24

DNA digested with StuI and HpaI (ICP0 gene), StuI and BamHI (exon 1
fragment), or PshAI and BssHII (exon 2 fragment). (C) Northern blot analysis
with an ICP0- versus GFP-specific probes hybridized to 10 µg total RNA isolated
from Vero cells that were uninfected (no virus) or were infected with the specified
HSV-1 viruses (MOI=10; RNA harvested 12 hours p.i.). (D) Two-color Western
blot analysis of cells that were uninfected (no virus) or were infected with the
specified HSV-1 viruses (MOI=10; protein harvested 18 hours p.i.). (E) Efficiency
of plaque formation by HSV-1 KOS, 0-GFP, 0+GFP12, 0+GFP24, or 0+GFP105 in
Vero cells relative to the number of plaques that formed in ICP0-complementing
L7 cells (mean ± sem; n=3 cultures per group).

3.1.2. Inefficient ICP0-GFP mRNA synthesis from HSV-1 0-GFP in the absence
of ICP0
ICP0 has been described as a promiscuous transcriptional activator (3,
20, 84). We reasoned that ICP0 should act in a positive-feedback loop to
promote mRNA synthesis from its own gene, the ICP0 gene. To test this
inference, an ICP0-expressing adenovirus vector, Ad-ICP0, was compared to a
control vector, Ad-n212 (Table 2), for its capacity to stimulate the expression of
the ICP0-GFP reporter gene embedded in the native LAT-ICP0 locus of HSV-1 0GFP.
In an initial test, cells were pre-treated with vehicle, Ad-n212, or Ad-ICP0,
and were inoculated 12 hours later with 2.5 pfu per cell of HSV-1 0-GFP. When
compared at 12 hours post-inoculation (p.i.), HSV-1 0-GFP expressed barely
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detectable levels of ICP0-GFP fluorescence in cells pre-treated with vehicle or Adn212 (Figure 2A). In contrast, pre-treatment with Ad-ICP0 allowed HSV-1 0-GFP
to express high levels of ICP0-GFP fluorescence (Figure 2A).
Northern blot analysis was conducted to determine if adenovirus-encoded
ICP0 stimulated ICP0-GFP mRNA accumulation in HSV-1 0-GFP-infected cells.
Vero cells were inoculated with 0 to 10 pfu of Ad-ICP0, and were inoculated 12
hours later with 2.5 pfu per cell of HSV-1 0-GFP. Northern blot analysis with a
GFP-specific probe demonstrated that Ad-ICP0 stimulated a 5-fold increase in
ICP0-GFP mRNA levels and did so in a dose-dependent manner (Figure 2B, D).
In contrast, Ad-n212 had no effect on ICP0-GFP mRNA levels (Figure 2C, D).
Therefore, exogenous ICP0 stimulated the accumulation of ICP0-GFP mRNA in
cells inoculated with HSV-1 0-GFP.
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Figure 2
ICP0 stimulates HSV ICP0-GFP gene expression.
(A) Photomicrographs of ICP0-GFP protein fluorescence in Vero cells inoculated
with 2.5 pfu per cell of HSV-1 0-GFP at 12 hours p.i., which were pre-treated with
either vehicle or 10 pfu per cell of Ad-n212 or Ad-ICP0 for 12 hours (20x
magnification). The TRE promoters in Ad-n212 and Ad-ICP0 were induced with
20 pfu per cell of Ad.CMV-TetOn and 10 µM doxycycline. (B and C) Northern
blot comparison of ICP0-GFP mRNA levels in cells that were uninfected (UI) or
were inoculated with 2.5 pfu per cell of HSV-1 0-GFP and 0 to 10 pfu per cell of
(B) Ad-ICP0 or (C) Ad-n212 (10 µg RNA per lane; RNA harvested at 12 hours
p.i.). (D) ICP0-GFP mRNA levels plotted as a function of the MOI of adenovirus in
the pre-treatment.
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3.1.3. Efficient ICP0-GFP mRNA synthesis from HSV-1 0-GFP when protein
synthesis is blocked
We were interested to determine how ICP0 influences the activity of the
ICP0-GFP gene in cells inoculated with HSV-1 0-GFP. One possibility was that
ICP0 induced mRNA synthesis from all of HSV-1 0-GFP’s genes, including the
ICP0-GFP gene (Figure 3A). A second possibility was that absence of ICP0
allowed a repressor such as PML (18) or HDAC1/2-CoREST-REST (20) to
silence all of HSV-1 0-GFP’s genes including the ICP0-GFP gene (Figure 3B, red
line). Under this latter hypothesis, ICP0 might stimulate ICP0-GFP mRNA
synthesis by antagonizing the repressor of the ICP0-GFP gene (Figure 3B, green
line). An experiment was conducted to evaluate the relative likelihood of these
two possibilities.
The effect of Ad-ICP0 versus Ad-n212 was compared in cells inoculated
with MOIs of 0.1 to 2.0 pfu per cell of HSV-1 0-GFP. As expected, HSV-1 0-GFP
expressed ICP0-GFP mRNA at all MOIs so long as ICP0 was provided in trans
from Ad-ICP0 (Figure 3C). In cells treated with the Ad-n212 control vector, HSV1 0-GFP failed to synthesize detectable levels of ICP0-GFP mRNA at MOIs below
0.9 pfu per cell (Figure 3D). At an MOI of 0.9 pfu per cell of HSV-1 0-GFP, 34fold higher levels of ICP0-GFP mRNA were noted in cells treated with Ad-ICP0
relative to cells treated with Ad-n212 (Figure 3E). Thus, efficient ICP0-GFP mRNA
accumulation was highly dependent on ICP0 at low multiplicities of HSV infection.
The mechanism by which ICP0 promoted ICP0-GFP mRNA accumulation
was unclear. Two possibilities included ICP0-dependent induction of ICP0-GFP
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mRNA synthesis (Figure 3A) or ICP0-dependent antirepression of ICP0-GFP
mRNA synthesis (Figure 3B). To differentiate between these possibilities, cells
were inoculated with Ad-ICP0 or Ad-n212 for twelve hours, and then cells were
treated with cycloheximide at the time of HSV-1 0-GFP inoculation. Thus, AdICP0’s capacity to stimulate ICP0-GFP mRNA accumulation could be evaluated in
the relative absence of other activators and/or repressors that formed in HSV-1
infected cells.
As expected, cells pre-treated with Ad-ICP0 expressed high levels of
ICP0-GFP mRNA despite the cycloheximide block to the synthesis of other HSV
proteins (Figure 3F, H). However, to our surprise, a similar result was observed
in Ad-n212-treated cells treated with cycloheximide (Figure 3G, H). Thus, when
protein synthesis was blocked in HSV-infected cells, ICP0 was no longer required
for the efficient synthesis of ICP0-GFP mRNA (Figure 3G). These findings argued
against the hypothesis that ICP0 was required to actively induce ICP0-GFP mRNA
synthesis (Figure 3A). Rather, the results suggested that ICP0 antagonized a
repressor of the ICP0-GFP gene that was synthesized de novo in HSV-infected
cells (Figure 3B, green line). Further tests were conducted to explore the validity
of this hypothesis.
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Figure 3
ICP0 de-represses HSV ICP0-GFP gene expression.
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(A and B) Alternative models by which ICP0 may stimulate ICP0-GFP gene
activity. (A) An ICP0 induction model predicts that ICP0 will be required to
induce the ICP0-GFP gene to its full activity (green line), whereas efficient ICP0-GFP
gene expression will not occur in the absence of ICP0 (blue line). (B) An ICP0
antirepression model predicts that i. a repressor will silence the ICP0-GFP gene
when ICP0 fails to accumulate (red line), ii. ICP0 prevents the repressor from
silencing the ICP0-GFP gene (green line), and iii. ICP0 is not required for efficient
ICP0-GFP gene expression when the repressor is absent (blue line). (C, D, F, G)
Northern blots of ICP0-GFP mRNA isolated from Vero cells inoculated with MOIs
of 0.1 to 2 pfu per cell of HSV-1 0-GFP (RNA harvested 12 hours p.i.; 10 µg per
lane). Vero cells were pre-treated with 10 pfu per cell of (C, F) Ad-ICP0 or (D, G)
Ad-n212 whose TRE promoters were induced with 20 pfu per cell of Ad.CMVTetOn and 10 µM doxycycline. Cells were treated with (C, D) vehicle or (F, G)
200 µM cycloheximide at the time of HSV-1 0-GFP inoculation. (E, H) ICP0-GFP
mRNA levels are plotted as a function of the MOI of HSV-1 0-GFP used to
inoculate Vero cells treated with (E) vehicle or (H) cycloheximide.
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3.1.4. Testing the predictions of a repression-antirepression model of ICP0
gene regulation
Three predictions followed from an hypothesis that HSV-1 ICP0 gene
activity was regulated by a process of repression and antirepression: i. HSV-1
ICP0- and ICP0+ viruses should express high and equivalent levels of ICP0
mRNA when synthesis of the repressor was blocked with cycloheximide (Figure
3B, blue line); ii. an HSV-1 ICP0+ virus should efficiently express ICP0 mRNA
when the repressor accumulated in HSV-infected cells (Figure 3B, green line);
and iii. an HSV-1 ICP0 - virus should exhibit little to no ICP0 mRNA synthesis
when the repressor accumulated in the absence of ICP0 (Figure 3B, red line).
As an initial test of these predictions, the relative expression of ICP0-GFP or
ICP0+GFP-105 fluorescent reporter proteins was compared in cells inoculated with
2.5 pfu per cell of HSV-1 0-GFP (ICP0-) versus HSV-1 0+GFP105 (ICP0+). In
vehicle-treated cells, HSV-1 0-GFP expressed barely detectable levels of ICP0GFP

fluorescence, whereas HSV-1 0+GFP105 expressed ICP0+GFP-105 fluorescence

to readily detectable levels (Figure 4A). In contrast, when protein synthesis was
inhibited for the first 6 hours of infection with cycloheximide, then both ICP0-GFP
and ICP0+GFP-105 fluorescent proteins accumulated to high levels by 6 hours postrelease from the cycloheximide block (Figure 4B). Quantification by flow
cytometry (85) demonstrated that ICP0-GFP and ICP0+GFP-105 fluorescent proteins
accumulated to high and equivalent levels following release from a cycloheximide
block (not shown).
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The relative expression of ICP0-GFP or ICP0+GFP-105 mRNA was compared
in cells inoculated with HSV-1 0-GFP versus 0+GFP105. When protein translation
was allowed to occur, HSV-1 0-GFP produced levels of ICP0-GFP mRNA that were
barely detectable between 3 and 12 hours p.i. (Figure 4C). When cycloheximide
was used to block protein synthesis, ICP0-GFP mRNA levels accumulated to
levels that were ~90 times background in HSV-1 0-GFP-infected cells (Figure 4C,
E). In contrast, the onset of protein translation did not prevent an ICP0+ virus,
HSV-1 0+GFP105, from expressing ICP0+GFP-105 mRNA to levels that were ~20
times background (Figure 4D, E). When protein synthesis was inhibited with
cycloheximide, HSV-1 0+GFP105 expressed ~5-fold higher levels of ICP0+GFP-105
mRNA (Figure 4D, E). As predicted, cycloheximide treatment allowed HSV-1 0GFP and 0+GFP105 to express high and equivalent levels of ICP0GFP mRNA
(Figure 4E). Control experiments verified that cycloheximide blocked HSV-1 L
mRNA synthesis (i.e., glycoprotein D mRNA), but had only a negligible effect on
cellular GAPDH mRNA levels (not shown).
These findings were consistent with the predictions of a repressionantirepression model of ICP0 gene regulation (Figure 3B). However, questions
remained about the identity of the de novo repressor that inhibited ICP0 mRNA
synthesis in HSV-1 0-GFP-infected cells. Alternatively, it was possible that
cycloheximide stimulated synthesis of all HSV mRNAs including ICP0-GFP mRNA
in a non-specific manner (16). Further experiments were conducted to
differentiate between these possibilities.
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Figure 4
De novo repression of HSV ICP0GFP mRNA accumulation is antagonized
by a GFP-tagged ICP0 protein.
(A and B) Photomicrographs of ICP0-GFP and ICP0+GFP-105 reporter protein
fluorescence in Vero cells 12 hours after inoculation with 2.5 pfu per cell of HSV1 0-GFP or 0+GFP105 (20x magnification). Cells were treated with either (A)
medium containing no drug (vehicle) from 0 to 12 hours p.i., or (B) 200 µM
cycloheximide from -0.5 to 6 hours p.i. followed by vehicle from 6 to 12 hours p.i.
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(C and D) Representative Northern blots of (C) ICP0-GFP mRNA or (D) ICP0+GFP105

mRNA harvested between 3 and 12 hours after inoculation with 2.5 pfu per

cell of HSV-1 0-GFP or 0+GFP105, respectively. Cells were treated with vehicle or
200 µM cycloheximide until the indicated time of RNA harvest (10 µg per lane).
(E) Mean ± sd of ICP0-GFP and ICP0+GFP-105 mRNA levels plotted as a function of
time of RNA harvest (n=2 per group).

3.1.5. Cycloheximide stimulates HSV ICP0 gene expression in a VP16dependent manner
VP16 carried in HSV virions binds six VP16-responsive elements in the
ICP0 promoter at the outset of infection (Figure 5A), and thus VP16 induces
ICP0 mRNA synthesis (5, 86). An experiment was conducted to determine if
cycloheximide’s effect on steady-state ICP0 mRNA levels was the result of a
VP16-dependent process, or rather was due to a myriad of non-specific effects
that should operate with equal efficiency in the presence or absence of VP16.
ICP0 mRNA accumulation was compared in cells inoculated with 2.5 pfu
per cell of wild-type HSV-1 KOS, the ICP0- virus n212 (73), or the VP16- virus
RP4 (74) (Table 1). When protein synthesis was allowed to occur, wild-type
HSV-1 expressed ICP0 mRNA to levels that were 28-fold above background,
whereas an ICP0- virus and VP16- virus expressed ICP0 mRNA to levels that
were only 4-fold above background (Figure 5B, C). When protein synthesis was
blocked with cycloheximide, the VP16+ viruses exhibited a robust increase in
ICP0 mRNA levels; consequently, wild-type HSV and the ICP0- virus expressed
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high and equivalent levels of ICP0 mRNA in cycloheximide-treated cells (Figure
5B, C). In contrast, the VP16- virus failed to efficiently express ICP0 mRNA in
either vehicle- or cycloheximide-treated cells (Figure 5C). Thus, cycloheximide
was incapable of stimulating ICP0 mRNA accumulation in the absence of VP16.
These data argued against the possibilities that cycloheximide might increase
ICP0 mRNA abundance by 1. decreasing the rate of ICP0 mRNA turnover, or by
2. stimulating a non-specific increase in the rate of transcription of all genes,
including the ICP0 gene. Rather, the data were consistent with a hypothesis that
cycloheximide blocked the formation of a de novo repressor of the ICP0 gene
that was dominant over the HSV-specific inducer of the ICP0 gene, VP16.
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Figure 5
Cycloheximide increases ICP0 gene expression
in a VP16-dependent manner.
(A) Schematic of ICP0 promoter, which indicates the positions of six distal VP16responsive elements (VREs), a proximal ICP4-binding site (4BS), and the TATAbox of the ICP0 gene. (B) Representative Northern blot of ICP0 mRNA in Vero
cells that were uninfected (UI) or were inoculated with 2.5 pfu per cell of HSV-1
KOS, n212 (ICP0-), or RP4 (VP16-), and which were treated with vehicle or 200
µM cycloheximide from -0.5 to 12 hours p.i., at which time total RNA was
harvested (10 µg per lane). (C) Mean ± sem of ICP0 mRNA levels in KOS, n212,
or RP4-infected cells (n=3 per group). Asterisks denote significant differences
between vehicle- and cycloheximide-treated cells inoculated with the same virus
(p<0.01; two-tailed Student’s t-test).
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3.1.6. De novo repression of HSV ICP0 gene expression is ICP4-dependent
There is evidence that inhibition of protein synthesis causes all of HSV’s
IE mRNAs to be overexpressed (87). One interpretation that has been offered is
that cycloheximide’s effect on HSV mRNA synthesis is global and non-specific
(16). However, there is a second, biologically important hypothesis that has not
been adequately considered. As well as HSV ICP4’s function as an essential
activator of E and L mRNA transcription (88), ICP4 may function as a repressor
of IE mRNA transcription (72). To determine if ICP4 contributed to de novo
repression of the ICP0 gene, ICP0 mRNA accumulation was compared in cells
inoculated with HSV-1 mutants deficient in the IE regulatory proteins ICP0,
ICP27, ICP22, or ICP4 (Table 1).
Regardless of their different genotypes, 2.5 pfu per cell of each HSV-1
VP16+ virus yielded high and equivalent levels of ICP0 mRNA in cycloheximidetreated cultures (Figure 6A). The ICP0- virus, n212, expressed very low levels of
ICP0 mRNA when protein translation was allowed to occur, whereas each of the
ICP0+ viruses expressed ICP0 mRNA to levels that were readily detectable in
vehicle-treated cells (Figure 6A). Wild-type HSV-1 KOS expressed 3.5 ± 0.4-fold
lower levels of ICP0 mRNA in vehicle-treated cells relative to cycloheximidetreated controls (Figure 6A, B). Likewise, the ICP27- and ICP22- viruses, d27-1
(68) and 22/n199 (70), expressed 4- to 5-fold less ICP0 mRNA in vehicle-treated
cells relative to cycloheximide-treated controls (Figure 6A, B). These results
suggested that the de novo repressor of ICP0 mRNA synthesis formed efficiently
in the absence of ICP22, ICP27, or the ~70 HSV E and L proteins whose
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synthesis was ICP27-dependent (68). In contrast, an ICP4- virus, n12 (71),
expressed high and equivalent levels of ICP0 mRNA in vehicle- and
cycloheximide-treated cells (Figure 6A, B). Therefore, de novo repression of
ICP0 mRNA accumulation appeared to be dependent upon the synthesis of
ICP4.
An independent test was conducted to corroborate this interpretation.
Vero cells were inoculated with 2.5 pfu per cell of HSV-1 KOS (ICP4+) or HSV-1
tsB21 (ICP4ts), which bears a temperature-sensitive lesion in the C-terminus of
ICP4; this mutation renders ICP4 non-functional at a temperature of 39.5 ºC (72).
At 34.0º, 37.0º, and 39.5ºC, wild-type HSV-1 KOS expressed ~3-fold less ICP0
mRNA in vehicle-treated cells relative to cycloheximide-treated controls (Figure
6C, D). Likewise, HSV-1 tsB21 expressed 2.9- and 2.3-fold less ICP0 mRNA in
vehicle-treated cells at 34.0º and 37.0ºC, respectively, relative to cycloheximidetreated controls (Figure 6C, D). In contrast, at the non-permissive temperature of
39.5ºC, HSV-1 tsB21 expressed equivalent levels of ICP0 mRNA in both vehicleand cycloheximide-treated cells (Figure 6C, D). Collectively these results
indicated that de novo repression of ICP0 mRNA accumulation was dependent
upon the synthesis of a biologically active form of HSV’s major transcriptional
regulator, ICP4.
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Figure 6
De novo repression of HSV ICP0 gene expression is ICP4-dependent.
(A) Representative Northern blot of ICP0 mRNA in Vero cells that were
uninfected (UI) or were inoculated with 2.5 pfu per cell of HSV-1 KOS (wild-type),
n212 (ICP0-), dl27-1 (ICP27-), 22/n199 (ICP22-), or n12 (ICP4-), which were
treated with vehicle or 200 µM cycloheximide from -0.5 to 6 hours p.i., at which
time total RNA was harvested (10 µg per lane). (B) Mean ± sem fold-reduction in
ICP0 mRNA levels in vehicle-treated cells relative to cycloheximide-treated
controls (fold-reduction = mRNA CHX ÷ mRNA VEH; n=4 per group). (C)
Representative Northern blot of ICP0 mRNA in Vero cells inoculated with 2.5 pfu
per cell of KOS (ICP4+) or HSV-1 tsB21 (ICP4 ts). Vehicle- and cycloheximidetreated cultures were incubated in CO2 chambers at 34.0, 37.0, or 39.5º C, and
total RNA was harvested at 6 hours p.i. (10 µg per lane). (D) Mean ± sem foldreduction in ICP0 mRNA levels plotted as a function of incubation temperature
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(fold-reduction = mRNA CHX ÷ mRNA VEH; n=4 per group). In panels B and D,
asterisks denote fold-reductions in ICP0 mRNA that significantly differ from the
value of 1, which is predicted by a null hypothesis that cycloheximide will have no
effect on ICP0 mRNA accumulation in HSV-infected cells (p<0.01; two-tailed
Student’s t-test).

3.1.7. De novo repression of HSV ICP0GFP reporter genes is ICP4-bindingsite-dependent
A consensus ICP4-binding site (ATCGTC) occurs 40-bp upstream of the
TATA box in the ICP0 promoter (38, 89). To determine if ICP4 binding to the
ICP0 promoter contributed to de novo repression of ICP0GFP mRNA synthesis,
the recombinant viruses HSV-1 0-4BS- and 0+4BS- were constructed which were
equivalent to HSV-1 0-GFP and 0+GFP105, respectively, but carried a 4-bp
deletion in the ICP4-binding site in the ICP0 promoter (Figure 7A).
A test was conducted to determine if disruption of the ICP4-binding site
might alleviate de novo repression of the ICP0-GFP gene. Vero cells were
inoculated with 5 pfu per cell of HSV-1 0-GFP or 0-4BS-, and ICP0-GFP
fluorescence was compared at 12 hours p.i. (Figure 7B). In cells inoculated with
HSV-1 0-GFP, ICP0-GFP fluorescence was barely visible (Figure 7B). In contrast,
ICP0-GFP fluorescence was readily detected in cells inoculated with HSV-1 0-4BS(Figure 7B). Likewise, ICP0+GFP-105 fluorescence accumulated to appreciably
higher levels in cells inoculated with HSV-1 0+4BS- relative to HSV-1 0+GFP105
(Figure 7C). These observations suggested that disruption of the proximal ICP4-
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binding site in the ICP0 promoter significantly alleviated de novo repression of
the ICP0-GFP and ICP0+GFP-105 genes.
To corroborate this interpretation, accumulation of the 3.5 kb ICP0GFP RNA
species was compared in cells inoculated with 5 pfu per cell of HSV-1 0-GFP, 04BS-, 0+GFP105, or 0+4BS- (Figure 7D). Each virus yielded high levels of ICP0GFP

or ICP0+GFP-105 mRNA in cycloheximide-treated cultures (Figure 7D). HSV-1

0-GFP exhibited a 13 ±1-fold repression of ICP0-GFP mRNA synthesis in vehicletreated cells relative to cycloheximide-treated controls (Figure 7D, 7E).
Disruption of the ICP4-binding site in the ICP0 promoter alleviated de novo
repression by 4-fold, and thus HSV-1 0-4BS- exhibited only a 3.3 ± 0.5-fold
reduction in ICP0-GFP mRNA in vehicle-treated cells (Figure 7D, 7E). Disruption
of the ICP4-binding site in the ICP0-GFP gene increased the efficiency of ICP0GFP
mRNA synthesis to the same extent as synthesis of a biologically active ICP0
protein; thus, HSV-1 0-4BS- and 0+GFP105 both exhibited a 3.3-fold reduction in
ICP0GFP mRNA levels in vehicle-treated cells relative to their respective
cycloheximide-treated controls (Figure 7D, 7E). Disruption of the ICP4-binding
site in the ICP0 promoter of HSV-1 0+4BS- resulted in a significant de-repression;
thus ICP0+GFP-105 mRNA levels in vehicle-treated cells infected with HSV-1
0+4BS- were only 2.1 ± 0.2-fold lower than cycloheximide-treated controls (Figure
7D, 7E). Collectively, these observations indicated that the magnitude of de
novo repression of ICP0GFP mRNA synthesis was significantly dependent upon
the ICP4-binding site proximal to the transcriptional start site of the ICP0 gene
(Figure 7A).
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Figure 7
De novo repression of ICP0GFP gene expression
is ICP4-binding-site-dependent.
(A) Schematic of the ICP4 DNA-binding site (4BS) deletion in HSV-1 0-GFP and
0+GFP105. All four viruses transcribe 3.5 kb ICP0GFP mRNAs, but HSV-1 0-4BSand 0+4BS- are deleted of bases -43 to -40 relative to the TATA box of the
ICP0GFP gene, which disrupts the consensus ICP4-binding site, 5’-ATCGTC-3’.
(B and C) Photomicrographs of ICP0-GFP and ICP0+GFP-105 fluorescent protein
accumulation in Vero cells 12 hours after inoculation with 5 pfu per cell of (B)
HSV-1 0-GFP versus 0-4BS- or (C) HSV-1 0+GFP105 versus 0+4BS- (20x
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magnification). (D) Representative Northern blots of ICP0GFP mRNA
accumulation in Vero cells that were uninfected (UI) or were inoculated with 5 pfu
per cell of HSV-1 0-GFP (ICP0-), 0-4BS- (ICP0-), 0+GFP105 (ICP0+), or 0+4BS(ICP0+), and which were treated with vehicle or 200 µM cycloheximide from -0.5
to 12 hours p.i., at which time total RNA was harvested (10 µg per lane). (E)
Mean ± sem fold-reduction in ICP0GFP mRNA levels in vehicle-treated cells
relative to cycloheximide-treated controls (fold-reduction = mRNA CHX ÷ mRNA VEH;
n=3 per group). Asterisks denote significant differences in fold-reduction in
ICP0GFP mRNA levels between the ICP0- viruses, HSV-1 0-GFP versus 0-4BS(p<0.001), and between the ICP0+ viruses, HSV-1 0+GFP105 versus 0+4BS(p<0.01; two-tailed Student’s t-test).

3.1.8. Adenovirus-encoded ICP4 substitutes for the de novo repressor of
the HSV ICP0-GFP gene
Our results raised the possibility that the de novo repressor of ICP0 mRNA
synthesis was not a cellular protein, but rather was the HSV ICP4 protein
because 1. loss of ICP4 function de-repressed ICP0 mRNA synthesis to the
same extent as cycloheximide treatment (Figure 6), and 2. a 4-bp deletion that
removed a single ICP4-binding site significantly alleviated de novo repression of
ICP0 mRNA synthesis (Figure 7). Based on this hypothesis, it was predicted that
pre-treatment of Vero cells with an ICP4-expressing adenovirus should negate
cycloheximide’s capacity to stimulate ICP0-GFP mRNA synthesis in HSV-1 0-GFPinfected cells.
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To test this prediction, Vero cells were infected with 0 to 250 pfu per cell
of Ad-ICP4 or a null control vector, and cells were inoculated 12 hours later with
HSV-1 0-GFP in the presence of cycloheximide. As expected, cells that received
no adenovirus vector and which were inoculated with HSV-1 0-GFP in the
presence of cycloheximide expressed high levels of ICP0-GFP mRNA (Figure 8A).
However, when Vero cells were pre-treated with Ad-ICP4, cycloheximide’s
capacity to stimulate ICP0-GFP mRNA synthesis dissipated and this inhibition was
adenovirus dose-dependent (Figure 8A). Despite cycloheximide treatment, the
highest MOI of Ad-ICP4 caused a 42-fold reduction in ICP0-GFP mRNA levels in
HSV-1 0-GFP-infected cells (Figure 8C). This was not a non-specific effect of the
adenovirus vector, as MOIs of 10 to 250 pfu per cell of Ad-null did not reduce the
efficiency of ICP0-GFP mRNA synthesis in HSV-1 0-GFP-infected cells treated with
cycloheximide (Figure 8A).
To verify that Ad-ICP4’s capacity to repress ICP0-GFP mRNA synthesis
was ICP4-binding-site-dependent, the experiment was performed in parallel with
HSV-1 0-4BS-. Ad-ICP4 had a modest effect on ICP0-GFP mRNA synthesis in
HSV-1 0-4BS--infected cells (Figure 8B). However, the potency of inhibition was
10-fold less than that observed in HSV-1 0-GFP-infected cells (Figure 8C).
Specifically, an MOI of 250 pfu per cell of Ad-ICP4 produced only a 4.4-fold
reduction in ICP0-GFP mRNA levels in HSV-1 0-4BS--infected cells treated with
cycloheximide (Figure 8C). Therefore, adenovirus-encoded ICP4 was sufficient
to substitute for the de novo repressor of the ICP0-GFP gene (Figure 8C).
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Figure 8
Exogenous ICP4 substitutes for the de novo repressor of the ICP0-GFP gene.
Representative Northern blots of ICP0-GFP mRNA levels in Vero cells treated with
200 µM cycloheximide and inoculated with 5 pfu per cell of (A) HSV-1 0-GFP or
(B) HSV-1 0-4BS- (10 µg total RNA per lane; time of harvest = 12 hours p.i.).
Twelve hours prior to HSV-1 inoculation, cells were pre-treated with 0, 10, 50, or
250 pfu per cell of Ad-ICP4 or Ad-null whose TRE promoters were induced with
20 pfu per cell of Ad.CMV-TetOn and 10 µM doxycycline. (C) Mean ± sem fold-
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reduction in ICP0-GFP mRNA levels in HSV-1 0-GFP or 0-4BS- infected cells as a
function of the MOI of Ad-ICP4 in the pre-treatment (n=3 per group). Asterisks
denote significant differences in Ad-ICP4-induced reductions in ICP0-GFP mRNA
levels between HSV-1 0-GFP and 0-4BS- (p < 0.001; two-way analysis of
variance).

3.1.9. ICP0 physically interacts with the repressor of its gene, ICP4, in HSVinfected cells
A physical interaction between ICP0 and ICP4 might begin to explain how
ICP0 influences ICP4’s activity as a transcriptional regulator. The available
evidence from far-Western blotting (81) and co-localization studies (80)
suggested that ICP0 may physically interact with ICP4. However, direct
evidence was lacking to address whether or not ICP0 and ICP4 physically
interact in the context of HSV-infected cells.
To address this gap in knowledge, a recombinant virus was constructed
that bore a FLAG epitope between amino acids 23 and 24 of ICP0, and which is
referred to as HSV-1 0+FLAG24 (Figure 9A). Southern blot analysis validated that
the FLAG coding sequence was inserted in both copies of the ICP0 gene, and
that HSV-1 0+FLAG24 grew with wild-type efficiency (not shown).
Immunofluorescent staining verified that HSV-1 0+FLAG24 expressed a FLAGtagged protein that exhibited a nuclear-staining pattern typical of ICP0 during the
IE phase of HSV infection (Figure 9B; 10 hours in cycloheximide → 6 hours in
actinomycin D).
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Immunoprecipitation experiments were performed to determine if ICP4
physically interacted with FLAG-tagged ICP0. Vero cells were inoculated with
vehicle or 5 pfu per cell of HSV-1 KOS or 0+FLAG24 in the presence of
cycloheximide (0 - 10 hours p.i.) followed by actinomycin D (10 - 16 hours p.i.),
such that only viral IE proteins were efficiently synthesized. Input levels of ICP4
and ICP0 in each immunoprecipitation reaction were equivalent, as verified by
Western blot analysis with monoclonal antibodies 58S and H1083, respectively
(Figure 9C, top panel). The remainder of each protein sample was
immunoprecipitated with an anti-FLAG antibody-agarose conjugate under
conditions of medium or high stringency, and immunoprecipitates were analyzed
for the presence of ICP4.
Significant amounts of ICP4 co-immunoprecipitated with FLAG-tagged
ICP0 from lysates of HSV-1 0+FLAG24-infected cells (Figure 9C, middle panel).
Non-specific pull down of ICP4 was negligible from lysates of uninfected Vero
cells or KOS-infected cells (Figure 9C). Therefore, the α-FLAG agarose only
appeared to pull down ICP4 when the FLAG epitope was present in ICP0.
Consistent with this interpretation, re-probing of the same blot with an ICP0specific monoclonal antibody, H1083, verified that anti-FLAG agarose efficiently
pulled down the 110 kDa FLAG-tagged ICP0, but did not pull down wild-type
ICP0 (Figure 9C, lower panel). We conclude that ICP0 and ICP4 do indeed
physically interact in HSV-infected cells, and propose that this interaction is likely
relevant in explaining how ICP0 antagonizes ICP4’s capacity to silence ICP0
mRNA synthesis from the HSV genome.
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Figure 9
ICP4 co-immunoprecipitates with FLAG-tagged ICP0.
(A) Schematic of 30-bp FLAG coding sequence insertion in exon 2 of the ICP0
gene in the HSV-1 recombinant virus, 0+FLAG24, in which a FLAG tag is inserted
between amino acids 23 and 24 of ICP0. (B and C) Vero cells were inoculated
with 5 pfu per cell of HSV-1 KOS (wild-type) or HSV-1 0+FLAG24, which were
treated with 200 µM cycloheximide from -0.5 to 10 hours p.i., released into
actinomycin D (10 µg / ml) from 10 to 16 hours p.i., and harvested for
immunofluorescent staining or immunoprecipitation. (B) Immunofluorescent
staining with a FLAG-specific antibody and AlexaFluor 594-conjugated secondary
antibody. (C) Cells were harvested in an NP40-based buffer containing 150 mM
NaCl (left panel) or RIPA buffer (right panel). The relative abundance of ICP4
and ICP0 was compared in 5% of total cell lysates (top panel), and the remainder
was immunoprecipitated with anti-FLAG agarose. Immunoprecipiates were
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washed in 500 mM NaCl (left panel) or RIPA buffer (right panel) prior to
electrophoresis and blotting, and were probed with ICP4-specific monoclonal
antibody 58S (middle panel), followed by re-probing with ICP0-specific
monoclonal antibody H1083 (bottom panel). The relative locations of ICP4 and
ICP0 are denoted by asterisks and open circles.

3.2. FUNCTION OF ICP0

3.2.1. GFP-tagged ICP0 is predominantly observed in the cytoplasm of HSVinfected cells
In cells transfected with the plasmids p0+GFP12, p0+GFP24, or p0+GFP105,
the ICP0+GFP-12, -24, or -105 proteins each accumulated in the nuclei of transfected
cells in a nuclear domain 10 (ND10)-like pattern (Fig. 10A-C; Ref. (30, 42)). In
contrast, the truncated ICP0-GFP protein was distributed in a nuclear and
perinuclear pattern in cells transfected with the plasmid p0-GFP (Fig. 10D).
When expressed in the context of HSV-1 infection, ICP0+GFP-12, -24, or -105 protein
was predominantly observed in the cytoplasm of virus-infected cells. For
example, ICP0+GFP-12 was predominantly observed in the cytoplasm of cells at the
outer edge of plaques formed by HSV-1 0+GFP12 (white arrow in Fig. 10E).
Likewise, the ICP0+GFP-24 and ICP0+GFP-105 proteins were primarily detected in the
cytoplasm of cells at the outer edge of plaques formed by HSV-1 0+GFP24 and
HSV-1 0+GFP105, respectively (white arrows in Fig. 10F, 10G). In contrast, the

50

ICP0-GFP peptide expressed by HSV-1 0-GFP accumulated throughout virusinfected cells (Fig. 10H).
The subcellular distribution of ICP0+GFP-24 protein was monitored in Vero
cells inoculated with 10 pfu per cell of HSV-1 0+GFP24. At 3 hours p.i., GFPtagged ICP0 was evident in the nuclei of many cells (Fig. 11A). However,
ICP0+GFP-24 only accumulated to high levels after 5 hours p.i., at which time the
protein had translocated to the cytoplasm of most HSV-1 0+GFP24-infected cells
(Fig. 11A). To determine if the translocation of ICP0+GFP-24 was replicationdependent, an HSV-1 ICP4- null virus was constructed, HSV-1 0+GFP24-Δ4. In
cells inoculated with HSV-1 0+GFP24-Δ4, the nuclear-to-cytoplasmic translocation
of ICP0+GFP-24 occurred with kinetics similar to the ICP4+ virus (Fig. 11B).
ICP0+GFP-24 was observed in bright perinuclear lines and globular bodies when
overexpressed from the ICP4- null virus (Fig. 11B). Intriguingly, this pattern of
cytoplasmic ICP0 was equivalent to the findings of Knipe and Smith (1986) (48),
who first described ICP0’s cytoplasmic distribution in cells inoculated with an
HSV-1 ICP4 mutant. Live-cell imaging of HSV-1 0+GFP24-Δ4-infected cells
demonstrated that the cytoplasmic bodies in which ICP0+GFP-24 protein
accumulated were highly mobile. In addition, cytoplasmic ICP0+GFP-24 was often
observed in linear arrays that encircled the nucleus (denoted by asterisks in Fig.
11B).
These observations raised questions both about the requirements for
ICP0’s nuclear-to-cytoplasmic translocation, and what function ICP0 might fulfill
in the cytoplasm of HSV-1 infected cells.
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Figure 10
GFP-tagged ICP0 is predominantly cytoplasmic in HSV-1 infected cells.
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(A) ICP0+GFP-12, (B) ICP0+GFP-24, (C) ICP0+GFP-105, or (D) ICP0-GFP as seen in Vero
cells 12 hours post transfection with the plasmids p0+GFP12, p0+GFP24,
p0+GFP105, or p0-GFP, respectively. Each plasmid was co-transfected with the
plasmid pBHad.CMV-VP16 to induce the ICP0 promoter and expression of GFPtagged ICP0. (E) ICP0+GFP-12, (F) ICP0+GFP-24, (G) ICP0+GFP-105, or (H) ICP0-GFP
as seen in Vero cells 40 hours post inoculation with the HSV-1 recombinant
viruses 0+GFP12, 0+GFP24, 0+GFP105, or 0-GFP, respectively. In each panel, an
entire plaque is shown on the right, and one edge of the plaque is magnified on
the left. White arrows denote HSV-1 infected cells in which GFP-tagged ICP0
was abundant in the cytoplasm, but was not evident in the nuclei of HSV-1
infected cells. Scale bar = 10 µm.
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Figure 11
ICP0+GFP-24 translocates to the cytoplasm of HSV-1 infected cells
in the presence or absence of ICP4.
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ICP0+GFP-24 protein in Vero cells inoculated with 10 pfu per cell of HSV-1 0+GFP24
(left column) or HSV-1 0+GFP24-∆4 (right column) between 3 and 8 hours p.i.
White asterisks denote cells in which ICP0+GFP-24 was observed in a linear pattern
encircling the nucleus of HSV-1 infected cells. Scale bar = 10 µm.

3.2.2. Cytoplasmic translocation of ICP0 is an early event in the HSV-1
replication cycle
To determine if cytoplasmic translocation of GFP-tagged ICP0 was
dependent upon the synthesis of other HSV-1 IE, E, or late (L) proteins, chemical
inhibitors were used to subdivide HSV-1 protein synthesis into its different
phases. Vero cells were treated with cycloheximide to block protein translation,
and cells were inoculated with 5 pfu per cell of HSV-1 0+GFP105. After allowing 6
hours for the accumulation of viral IE mRNAs, cycloheximide was removed and
cultures were released into medium containing either actinomycin D (mRNA
synthesis inhibitor, Ref. (90)), acyclovir (DNA synthesis inhibitor, Ref. (91)) or
vehicle (no inhibitor).
In HSV-1 0+GFP105-infected cells released into medium containing
actinomycin D, ICP0+GFP-105 remained in the nuclei of >90% of cells at 1 and 4
hours post-release from a cycloheximide block (Fig. 12A). Thus, translocation of
ICP0+GFP-105 failed to occur when only viral IE proteins were efficiently expressed.
When HSV-1 0+GFP105-infected cells were released into medium containing
acyclovir (IE and E proteins expressed), ICP0+GFP-105 was initially observed in
nuclei, but translocated to the cytoplasm of most cells by 4 hours post-release
(Fig. 12A). Likewise, when cycloheximide treatment was followed with vehicle,
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ICP0+GFP-105 translocated to the cytoplasm with similar kinetics (Fig. 12A).
Parallel tests with HSV-1 0+GFP12, 0+GFP24, and 0+GFP24-Δ4 yielded equivalent
results (not shown). These results suggested that the nuclear-to-cytoplasmic
translocation of ICP0+GFP-105 occurred during the E phase of HSV-1 replication.
To determine if these results were relevant to wild-type ICP0, similar tests
were performed with wild-type HSV-1 strain KOS (69). When cycloheximide
treatment was followed with actinomycin D, wild-type ICP0 was retained in the
nuclei of KOS-infected cells at 4 hours post-release (Fig. 12B). In contrast, when
cycloheximide treatment was followed with acyclovir or vehicle, wild-type ICP0
translocated to the cytoplasm by 4 hours post-release and was observed in
globular and linear structures that encircled the nuclei of >90% of KOS-infected
cells (Fig. 12B). Therefore, both GFP-tagged ICP0 and wild-type ICP0 were
predominantly nuclear during the IE phase of viral infection, but rapidly
translocated to the cytoplasm when viral E protein synthesis was allowed to
occur.
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Figure 12
ICP0 translocates to the cytoplasm during early phase of HSV-1 replication.
(A) ICP0+GFP-105 protein in Vero cells inoculated with HSV-1 0+GFP105 following
release from cycloheximide block. Cultures were inoculated with 5 pfu per cell of
0+GFP105, treated with 200 μM cycloheximide from -0.5 to 6 hours p.i., and
released into medium containing actinomycin D (10 µg / ml), 300 µM acyclovir, or
vehicle. Cultures were photographed at 7 and 10 hours p.i. (B) ICP0 in HSV-1
KOS-infected Vero cells following release from cycloheximide block. Cultures
were inoculated with 5 pfu per cell of KOS, treated with cycloheximide from -0.5
to 6 hours p.i., released into medium containing actinomycin D, acyclovir, or
vehicle, and fixed for immunofluorescent staining at 7 and 10 hours p.i. White
asterisks denote cells in which ICP0 was observed in a linear pattern encircling
the nucleus of HSV-1 infected cells. Scale bar = 10 µm.
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3.2.3. ICP0+GFP-105 disperses linear structures in the cytoplasm of HSV-1
infected cells
The cytoplasmic structures in which ICP0 accumulated did not appear to
be mitochondria, lysosomes, Golgi apparatus, or endoplasmic reticulum (ER)
based upon the failure of ICP0 to co-localize with MitoTracker dye (92),
LysoTracker dye (93), Golgi marker β-COP (94), or the ER marker calreticulin
(95). Moreover, in early attempts to isolate the fluorescent-ICP0 labeled
cytoplasmic bodies by density gradient sedimentation, it was noted that the
bodies rapidly dispersed upon homogenization of cells in ice-cold buffer (not
shown). To gather further clues about the nature of these structures, live-cell
imaging was used to study the dynamics of accumulation of ICP0+GFP-105 in the
cytoplasm of HSV-1 0+GFP105-infected cells.
Cycloheximide was used to alleviate ICP4-dependent repression of the
ICP0GFP gene (39), such that ICP0+GFP-105 mRNA could accumulate to high levels
and be synchronously translated upon cycloheximide release (39). At 1 hour
post-release, ICP0+GFP-105 was observed exclusively in the nuclei of HSV-1
0+GFP105-infected cells (Table 3). Between 2 and 4 hours post-release,
ICP0+GFP-105 had partially or completely translocated to the cytoplasm of >90% of
HSV-1 0+GFP105-infected cells (Table 3). At 4 hours post-release, ICP0+GFP-105
was observed in linear cytoplasmic structures in 16 ± 1% of 0+GFP105-infected
cells (Table 3). However, by 6 hours post-release, ICP0+GFP-105 was rarely
observed in linear cytoplasmic structures (Table 3).
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We considered the possibility that ICP0+GFP-105 might trigger the dispersal
of cytoplasmic structures in much the same manner that ICP0 triggers the
dispersal of PML nuclear bodies (30, 42). To test this hypothesis, a recombinant
virus was constructed, HSV-1 0ΔRING, which encoded a GFP-tagged ICP0∆RING
protein that was deleted of amino acids 105 – 221, and thus lacked ICP0’s RINGfinger domain (15). When cycloheximide-release experiments were performed in
cells inoculated with HSV-1 0ΔRING, the ICP0∆RING protein accumulated in linear
cytoplasmic structures between 2 and 6 hours post-release (Table 3).
Intriguingly, ICP0∆RING was rarely observed in globular bodies, but rather the
protein was observed almost exclusively in linear cytoplasmic structures (Table
3). These findings suggested that ICP0∆RING stably accumulated in linear
cytoplasmic structures, whereas ICP0+GFP-105 triggered the dispersal of these
structures upon accumulating at these sites.
To test this hypothesis, live-cell imaging was used to track the fate of
linear structures in which ICP0+GFP-105 accumulated. Cells were inoculated with
HSV-1 0+GFP105 and time-lapse photography was conducted between 4.0 and
4.5 hours post-release from a cycloheximide block. Linear, cytoplasmic arrays of
ICP0+GFP-105 that initially encircled the nucleus were found to be unstable, and
dispersed into smaller, globular bodies over a 10- to 20-minute time frame (Fig.
13A). In contrast, experiments with HSV-1 0ΔRING demonstrated that the
ICP0∆RING protein stably accumulated in linear cytoplasmic structures which grew
visibly in length and thickness between 4.0 and 4.5 hours post-release (Fig.
13B). This trend continued until 6 hours post-release, at which time the
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experiment was terminated (not shown). Therefore, ICP0+GFP-105 translocated to
the cytoplasm, accumulated in linear cytoplasmic structures, and then triggered
the dispersal of these structures in a RING-finger-dependent manner.

Table 3
Subcellular distribution of ICP0GFP in HSV-1 infected cells at times after
release from a cycloheximide block a

Virus

0+GFP105

Subcellular distribution b

Cytoplasmic pattern e

ICP0GFP only

ICP0GFP in

ICP0GFP

ICP0GFP

in nucleus

cytoplasm

in lines

in globules

1

100 ± 0 c

0 ± 0d

0 ± 0f

0 ± 0g

2

9±1

91 ± 1

2±0

98 ± 0

3

2±0

98 ± 0

10 ± 1

90 ± 1

4

2±0

98 ± 0

16 ± 1

77 ± 1

5

2±0

98 ± 0

11 ± 1

81 ± 1

6

1±0

99 ± 0

1±0

87 ± 1

1

100 ± 0

0±0

0±0

0±0

2

40 ± 2

60 ± 2

96 ± 0

4±0

3

39 ± 1

61 ± 1

97 ± 0

3±0

4

34 ± 1

66 ± 1

99 ± 0

1±0

5

26 ± 1

74 ± 1

99 ± 0

1±0

6

22 ± 1

78 ± 1

99 ± 0

1±0

Hours

0ΔRING

a

Vero cells were inoculated with 5 pfu per cell of HSV-1 0+GFP105 or HSV-1
0∆RING in the presence of 200 μM cycloheximide from -0.5 to 10 hours p.i., and
were released into medium containing no drugs. Cultures were photographed
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between 1 and 6 hours post-release to record the position of all nuclei (visualized
with Hoechst 33342) and the subcellular localization of ICP0+GFP-105 or ICP0∆RING.
b

Frequency of cells in which ICP0+GFP-105 or ICP0∆RING was observed exclusively in
the nucleus (left column) versus cells in which proteins were observed in either
the cytoplasm and nucleus or just in the cytoplasm (right column).

c

Frequency of cells (mean ± sem) in which ICP0+GFP-105 or ICP0∆RING was
observed exclusively in the nucleus. The frequency reported at each time point
was calculated as 100 x number of cells in which ICP0GFP was observed solely in
the nucleus ÷ number of ICP0GFP+ cells. Each value is based on n = 4
independent cultures, and each estimate of frequency was based on n=400
Hoechst+ cells. Between 4 and 6 hours post-release, 95 ± 1% of cells in HSV-1
inoculated cultures were positive for the ICP0+GFP-105 or ICP0∆RING proteins.

d

Frequency of cells (mean ± sem) in which ICP0+GFP-105 or ICP0∆RING was
observed in the cytoplasm and nucleus, or just in the cytoplasm. Frequencies
were calculated by the method described in footnote c.

e

Frequency of ICP0+GFP-105 or ICP0∆RING accumulating in linear arrays (left column)
versus globular patterns (right column) in the cytoplasm of HSV-1 infected cells.

f

Frequency of cells (mean ± sem) in which ICP0+GFP-105 or ICP0∆RING were
observed in linear cytoplasmic arrays that encircled Hoechst+ nuclei. The
frequency reported at each time point was calculated as 100 x number of cells
containing linear arrays of ICP0GFP protein ÷ number of cells in which ICP0GFP
was evident in the cytoplasm. Each value is based on n = 4 independent
cultures, and each estimate of frequency was based on n=400 Hoechst+ cells.

g

Frequency of cells (mean ± sem) in which ICP0+GFP-105 or ICP0∆RING were
observed in globular, cytoplasmic bodies, which was calculated as described in
footnote f.
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Figure 13
ICP0+GFP-105 disperses linear cytoplasmic structures
in a RING-finger-dependent manner.
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Vero cells were inoculated with 5 pfu per cell of (A) HSV-1 0+GFP105 or (B) HSV1 0∆RING in the presence of 200 μM cycloheximide from -0.5 to 10 hours p.i.,
and were released into medium containing no drugs. Between 4.0 and 4.5 hours
post-release, time-lapse photographs were collected of the ICP0+GFP-105 or
ICP0∆RING proteins that encircled the nucleus of HSV-1 infected cells. Scale bar
= 10 µm.

3.2.4. ICP0 co-localizes with disrupted microtubule networks in HSV-1
infected cells
The linear cytoplasmic structures in which ICP0+GFP-105 transiently
accumulated were reminiscent of microtubule bundles formed by HSV-1’s VP22
protein (56). Therefore, we considered the possibility that ICP0+GFP-105 and
ICP0∆RING proteins might associate with host cell microtubules. To test this
hypothesis, cycloheximide-release experiments were performed in cells
inoculated with HSV-1 0ΔRING, HSV-1 0+GFP105, or wild-type HSV-1 KOS. At 4
hours post-release, cells were fixed and immunofluorescently stained for αtubulin and ICP0.
In uninfected Vero cells, α-tubulin staining revealed a normal network of
microtubules that radiated from the microtubule-organizing center at the
periphery of the nucleus (Fig. 14). In cells inoculated with HSV-1 0ΔRING, αtubulin staining revealed extensive thickening of microtubules into elongated
bundles that circumscribed the nucleus, and co-localized with the ICP0∆RING
protein (Fig. 14). In cells inoculated with HSV-1 0+GFP105, α-tubulin staining
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revealed that the microtubule network had dispersed into small α-tubulin+,
globular bodies that co-localized with ICP0+GFP-105 (Fig. 14). In cells inoculated
with wild-type HSV-1 KOS, the host cell microtubule network was also disrupted,
and α-tubulin was dispersed into α-tubulin+ globular bodies that co-localized with
ICP0 (Fig. 14). Although the ICP0∆RING protein bundled microtubules, it failed to
trigger their dispersal into globular bodies (Fig. 14). These results raised the
possibility that HSV’s E3 ligase, ICP0, might contribute to microtubule
disassembly in HSV-infected cells (55). Further experiments were conducted to
test the validity of this hypothesis.
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Figure 14
ICP0 co-localizes with reorganized microtubules in HSV-1 infected cells.
Immunofluorescent staining of Vero cells that were uninfected (no virus) or that
were inoculated with 5 pfu per cell of HSV-1 0ΔRING, HSV-1 0+GFP105, or wild65

type HSV-1 strain KOS. Cells were inoculated in the presence of 200 μM
cycloheximide from -0.5 to 10 hours p.i., and were released into medium
containing no drugs. At 4 hours post-release, uninfected cells and KOS-infected
cells were fixed and stained with antibodies against α-tubulin (rabbit IgG, Alexa
Fluor 594) and ICP0 (mouse IgG, fluorescein). Nuclei were counterstained with
the DNA-binding dye Hoechst 33342. HSV-1 0ΔRING and 0+GFP105-infected
cells were fixed and stained for α-tubulin, and the ICP0∆RING and ICP0+GFP-105
proteins were visualized using their GFP fluorophores. Scale bar = 10 µm.

3.2.5. ICP0∆RING protein accumulates in linear structures that are
nocodazole-sensitive
If microtubules did indeed provide the underlying scaffold on which
ICP0∆RING protein accumulated in linear arrays (Fig. 13, 14), then inhibition of
microtubule polymerization with nocodazole (96) should recapitulate the effect of
ICP0’s RING finger domain. Specifically, nocodazole treatment, like wild-type
ICP0, should trigger microtubule disassembly and cause linear accumulations of
ICP0∆RING protein to disperse into smaller bodies. To test this prediction, cells
were infected with HSV-1 0ΔRING in the presence of cycloheximide for 10 hours,
and were released into medium containing no inhibitor. Four hours later, the
stability of linear arrays of ICP0∆RING protein was compared in the presence or
absence of nocodazole.
In the absence of nocodazole, ICP0∆RING protein stably accumulated in
linear structures that encircled the nucleus of HSV-1 0ΔRING-infected cells
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between 4.0 and 4.5 hours post-release (Fig. 15A). In contrast, nocodazole
treatment caused linear accumulations of ICP0∆RING protein to disperse into small
globular bodies within 10 to 30 minutes, and the time required for dispersal
varied in proportion to the thickness of each bundle (Fig. 15B). Nocodazoleinduced, ICP0∆RING+ globular bodies were identical in appearance to α-tubulin+
globular bodies that co-localized with ICP0 and ICP0+GFP-105 (Fig. 14).
Independent tests verified that nocodazole-induced, ICP0∆RING+ globular bodies
were also α-tubulin+ (not shown).
These observations indicated that the linear cytoplasmic structures in
which ICP0∆RING protein accumulated were indeed microtubule bundles. This
finding was also consistent with our prior observation that ICP0+GFP-105-containing
bodies rapidly dispersed upon homogenization in ice-cold buffer; a condition
known to cause depolymerization of microtubules (97).
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Figure 15
ICP0∆RING accumulates in linear structures that are nocodazole-sensitive.
Vero cells were inoculated with 5 pfu per cell of HSV-1 0ΔRING in the presence
of 200 μM cycloheximide from -0.5 to 10 hours p.i., and were released into
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medium containing no drugs. At 4 hours post-release, a representative field of
view was chosen, and cells were treated with (A) vehicle or (B) 10 μg/ml
nocodazole. Between 4.0 and 4.5 hours after cycloheximide release, time-lapse
photographs were captured at 10-minute intervals. White asterisks denote cells
in which ICP0∆RING was observed in a continuous, linear pattern encircling the
nucleus of HSV-1 infected cells. Scale bar = 10 µm.

3.2.6. ICP0 is necessary for efficient dispersal of microtubules in HSV-1
infected cells
It is well established that the host cell microtubule network is disrupted
during the course of HSV-1 infection (55, 98, 99). However, it is unclear what
process triggers microtubule reorganization in HSV-1 infected cells. We
questioned whether this event might be ICP0-dependent. To test this
hypothesis, α-tubulin and ICP0 staining were compared in Vero cells that were
uninfected (UI) or were inoculated with HSV-1 KOS, HSV-1 0+GFP105, or an
ICP0- null virus, HSV-1 0-GFP. Cells were inoculated with 5 pfu per cell of each
virus in the presence of cycloheximide for 10 hours to allow high and equivalent
levels of ICP0+ and ICP0- mRNAs to accumulate (39). At 1 and 4 hours postrelease, a normal distribution of α-tubulin staining was noted in uninfected Vero
cells; specifically, microtubules radiated from the microtubule-organizing center
on one side of the nucleus (Fig. 16A). At 1 hour post-release, ICP0 and
ICP0+GFP-105 were observed in the nuclei of cells infected with HSV-1 KOS and
0+GFP105 (Fig. 16A). Importantly, α-tubulin staining was always normal when
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ICP0 or ICP0+GFP-105 were confined to the nucleus (Fig. 16A). However, at 4
hours post-release, ICP0 and ICP0+GFP-105 had translocated to the cytoplasm and
this event coincided with dispersal of microtubules in KOS- and 0+GFP105infected cells, respectively (Fig. 16B). Specifically, microtubule-organizing
centers were no longer discernible, and α-tubulin was dispersed into globular
bodies that co-localized with ICP0 or ICP0+GFP-105 (Fig. 16B). In contrast, at 1
and 4 hours post-release, cells inoculated with HSV-1 0-GFP retained an intact
microtubule network that radiated from a perinuclear microtubule-organizing
center (Fig. 16A, 16B). Likewise, at 6 and 8 hours post-release, microtubule
networks remained intact in HSV-1 0-GFP-infected cells (not shown). Therefore,
synthesis of ICP0 appeared to be necessary for the efficient dismantling of
microtubule networks that normally occurs in HSV-1 infected cells (55).
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Figure 16
ICP0 is necessary for the dissolution of microtubule networks
in HSV-1 infected cells.
Vero cells were uninfected or were inoculated with 5 pfu per cell of HSV-1 strain
KOS, HSV-1 0+GFP105, or HSV-1 0-GFP in the presence of 200 μM cycloheximide
from -0.5 to 10 hours p.i., and were released into medium containing no drugs
until the time of fixation. At (A) 1 hour post-release or (B) 4 hours post-release,
uninfected and KOS-infected cells were fixed and stained with antibodies against
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α-tubulin (rabbit IgG) and ICP0 (mAb H1083). HSV-1 0+GFP105 or 0-GFPinfected cells were fixed and stained for α-tubulin, and ICP0+GFP-105 and ICP0-GFP
proteins were visualized using their GFP fluorophores. Nuclei were
counterstained with the DNA-binding dye Hoechst 33342. Scale bar = 10 µm.

3.2.7. ICP0 is sufficient to dismantle microtubule networks in transfected
cells
The HSV-1 proteins US11 (100), UL34 (101), VP26 (102) and VP22 (56)
interact with host cell microtubules. Thus, ICP0 might be one of many HSV
proteins that is required to disperse the intracellular ‘freeway system’ that is the
cell’s microtubule network (103). Alternatively, synthesis of ICP0 alone might be
sufficient to disperse cellular microtubules. To differentiate between these
possibilities, Vero cells were transfected with pICP0, p0+GFP105, or p0ΔRING to
determine if synthesis of ICP0 proteins affected the subcellular distribution of αtubulin, one of the principal structural subunits of the hollow, polymeric tubes
known as microtubules (104).
A normal distribution of α-tubulin staining was noted in mock-transfected
Vero cells at 12 and 24 hours post-transfection. Specifically, microtubules
radiated from the organizing center on one side of the nucleus, and α-tubulin
staining was not observed in the nuclei of mock-transfected Vero cells (Fig. 17A,
17B). Consistent with prior results (Fig. 10A-10C), wild-type ICP0 and ICP0+GFP105

were observed in the nuclei of cells transfected with pICP0 and p0+GFP105 at

12 hours post-transfection (Fig. 17A). At this early time, a normal distribution of
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α-tubulin staining was noted in the cytoplasm, but to our surprise significant
amounts of α-tubulin were present in the nuclei and co-localized with wild-type
ICP0 and ICP0+GFP-105 (Fig. 17A). Control staining with individual antibodies
verified that the appearance of co-localization was not an unintended
consequence of bleedover between the red and green channels (not shown). In
cells transfected with p0ΔRING, the ICP0∆RING protein was also observed in the
nuclei of cells at 12 hours post-transfection, and a normal distribution of α-tubulin
staining was noted in the cytoplasm. However, large amounts of α-tubulin were
present in the nuclei of transfected cells, and α-tubulin co-localized with the
ICP0∆RING protein (Fig. 17A).
At 24 hours post-transfection, wild-type ICP0 and ICP0+GFP-105 were
observed in the nuclei and cytoplasm of cells transfected with pICP0 and
p0+GFP105, respectively (Fig. 17B). Translocation of ICP0 or ICP0+GFP-105 to the
cytoplasm consistently correlated with 1. dissolution of the host cell microtubuleorganizing center and microtubule network, and 2. co-localization of α-tubulin
with ICP0 or ICP0+GFP-105 in small, globular bodies in the cytoplasm (Fig. 17B).
Likewise, 24 hours after transfection with p0ΔRING, ICP0∆RING protein colocalized with α-tubulin in elongated microtubule bundles (Fig. 17). Therefore,
synthesis of the ICP0ΔRING protein was sufficient to trigger bundling, but not
dispersal of microtubules. In contrast, wild-type ICP0 was sufficient to trigger a
complete dispersal of host cell microtubules.
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Figure 17
ICP0 is sufficient to trigger the dissolution
of host cell microtubule networks.
Vero cells were mock-transfected or were transfected with a VP16-expressing
plasmid and pICP0, p0+GFP105, or p0∆RING. At (A) 12 hours post-transfection or
(B) 24 hours post-transfection, mock- and pICP0-transfected cells were fixed and
stained with antibodies against α-tubulin (rabbit IgG) and ICP0 (mAb H1083).
Cells transfected with p0+GFP105 or p0ΔRING were fixed and stained to visualize
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α-tubulin, and the ICP0∆RING and ICP0+GFP-105 proteins were visualized using their
GFP fluorophores. Scale bar = 10 µm.

3.2.8. ICP0 translocation and microtubule dispersal in a single HSV-1
plaque
High MOIs and cycloheximide-release experiments allowed robust
visualization of ICP0 and co-localization of ICP0 with microtubule breakdown
products. These tests left unaddressed the question of whether or not ICP0
actually translocates and/or dismantles microtubule networks during the normal
progression of HSV-1 infection. To address this issue, Vero cells were
inoculated with wild-type virus at an MOI of 0.0001 pfu per cell, and the
distribution of ICP0 and α-tubulin was analyzed in isolated HSV-1 plaques at 40
hours p.i. A single, representative plaque is considered to illustrate our findings
(Fig. 18).
With the enhanced sensitivity of immunofluorescent staining (versus direct
imaging of GFP fluorescence, Fig. 10), low levels of ICP0 were detectable in the
nuclei of cells at the outermost, advancing edge of HSV-1 plaques (• symbols,
Fig. 18A). In those HSV-1 infected cells in which ICP0 was observed solely in
the nucleus, the perinuclear pattern of microtubule staining remained normal (•
symbols, Fig. 18B). Behind this advancing front, a second row of HSV-1 infected
cells was observed in which ICP0 was far more abundant and predominantly
localized to the cytoplasm of HSV-1 infected cells (X symbols, Fig. 18A). When
ICP0 accumulated in the cytoplasm of HSV-1 infected cells, gross reorganization
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of the cellular microtubule network was observed (X symbols, Fig. 18B).
Moreover, α-tubulin was frequently observed reorganized into linear structures or
globular bodies that co-localized with wild-type ICP0 (white arrows, Fig. 18).
Therefore, we conclude that regardless of MOI, a nuclear-to-cytoplasmic
translocation of ICP0 routinely occurs in HSV-1 infected cells, and the timing of
ICP0’s translocation to the cytoplasm coincides with a massive reorganization of
the host cell’s microtubule network.
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Figure 18
Translocation of ICP0 and disruption of host cell microtubules
in a single HSV plaque.
Vero cells were inoculated with wild-type HSV-1 KOS virus at an MOI of 0.0001
pfu per cell, and cells were fixed and stained at 40 hours p.i. using antibodies
against (A) ICP0 and (B) α-tubulin. Nuclei were counterstained with the DNAbinding dye Hoechst 33342. Cells in which ICP0 was observed solely in the
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nucleus are denoted by a circle (•) to the right of the nucleus. Cells in which
ICP0 was prominent in the cytoplasm are denoted with an ‘X’ to the right of the
nucleus. White arrows denote cells in which α-tubulin was not only dispersed,
but also co-localized with ICP0. Scale bar = 10 µm.
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CHAPTER 4: DISCUSSION

At the beginning of the dissertation, I set out to address the questions 1)
how is ICP0 gene regulated, and 2) what function does ICP0 assume during HSV
infection. Regarding to the first question, the results of our study suggest that
ICP0 gene is differentially regulated by virus-encoded repressor ICP4 and virusencoded antirepressor ICP0, which hints herpesviruses might deploy
bacteriophage λ-like strategy to regulate their genes. Regarding to the second
question, the results of our study show that ICP0 dismantles the microtubule
networks of HSV-infected cells, which indicates ICP0 might play a previously
unrecognized role in the cytoplasm, and suggests a general function of many
other viral E3 ligases. The specific discussion regarding each question is
detailed below:

4.1. GENE REGULATION OF ICP0

4.1.1. Identification of an ICP0-antagonized repressor of HSV mRNA
synthesis
HSV routinely establishes latent infections in its human host. During the
latent phase of infection, most of the HSV genome is transcriptionally silent. It is
unclear how the HSV genome is silenced, but it is generally agreed that
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synthesis of ICP0 destabilizes repression and thus triggers reactivation of mRNA
synthesis from latent HSV genomes (10, 11, 105).
The search for an ICP0-antagonized transcriptional repressor has led
investigators to consider the possibility that PML and Sp100 (18), IRF-3 and IRF7 (26), and centromere proteins CENP-B and CENP-C (27, 28) may represent
the repressors of the HSV genome that are antagonized by ICP0. Although ICP0
may alter the subcellular distribution, stability, or function of these proteins, there
is no direct evidence that these proteins are capable of restricting mRNA
synthesis from the HSV genome. Likewise, it has been postulated that
epigenetic silencing may be the ICP0-antagonized repressive mechanism that is
capable of silencing the HSV genome (21, 53). However, no specific histone
deacetylase or histone mark has been associated with more than a 2-fold
reduction in HSV mRNA synthesis (19, 20, 53, 106).
Although an ICP0-antagonized repressor has not been identified, it would
be reasonable to expect that the repressive entity: 1. should be necessary and
sufficient to restrict the synthesis of one or more HSV mRNAs; 2. should be
unable to silence HSV mRNA synthesis when ICP0 accumulates; and 3. may
physically interact with ICP0. The results of the current study establish that
HSV’s major transcriptional regulator, ICP4, meets these criteria, and thus
appears to be the first bona fide ICP0-antagonized repressor of HSV mRNA
synthesis.
The results clarify that ICP4 is capable of silencing mRNA synthesis from
the ICP0 gene when ICP0 fails to accumulate. At low MOIs, HSV ICP0- viruses
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establish quiescent infections in 99% of infected cells (12, 13). Intriguingly, ICP4
accumulates to detectable levels in >85% of cells that become quiescently
infected with HSV ICP0- viruses (107). Thus, further studies will be required to
determine if 1. ICP4 often accumulates in the absence of ICP0 in HSV
quiescently infected cells (108-110), and if 2. ICP4 may contribute to quiescent
HSV infections by restricting mRNA synthesis from HSV IE genes.

4.1.2. Differential regulation of ICP0 mRNA synthesis in HSV-infected cells
There is anecdotal evidence that the ICP0 gene is differentially regulated
in HSV-infected cells, but it remains unclear how such regulation is achieved.
The HSV latency-associated transcripts (LATs) have been discussed for their
potential to repress ICP0 gene expression (111, 112). Likewise, VP16’s capacity
to function as a transactivator of IE genes has been considered as a potential
target of differential regulation (113-115). However, it remains unclear that LATs
or VP16 are sufficient to explain how the ICP0 gene is regulated.
The ICP4-binding site in the ICP0 promoter was identified 20 years ago as
a potential means by which ICP4 might regulate ICP0 mRNA synthesis (89).
When studied in the context of HSV ICP0+ viruses, some investigators concluded
that ICP4’s effect on ICP0 gene expression was negligible (37). Other
investigators noted that ICP4 produced a modest decrease in ICP0 mRNA levels
in the context of ICP0+ viruses (38), but ICP4’s full potential to silence ICP0
gene expression went unrecognized.
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The current study demonstrates that the ICP0 gene is differentially
regulated by three HSV proteins, VP16, ICP4, and ICP0, whose relationship to
one another is not resolved. Functionally, the results suggest that VP16 and
ICP4 ‘push’ ICP0 mRNA synthesis in opposite directions, and accumulation of
ICP0 dictates which way this equilibrium will tilt. When ICP0 fails to accumulate,
ICP4 is capable of silencing ICP0 mRNA synthesis despite VP16 in the tegument
of virions (Figure 3-6; ICP0- treatments). When formation of the de novo
repressor is blocked with cycloheximide, VP16’s full capacity to transactivate the
HSV-1 ICP0 gene is revealed (Figure 5). If ICP0 accumulates, ICP4 no longer
represses ICP0 mRNA synthesis (Figure 3-6; ICP0+ treatments). These findings
suggest that a hierarchy exists in the HSV regulatory scheme in which i. ICP0dependent antirepression of the ICP0 gene is dominant over ii. ICP4-dependent
repression of the ICP0 gene, which is dominant over iii. VP16-dependent
induction of the ICP0 gene. Therefore, while VP16 induces transcription of both
the ICP4 and ICP0 genes, the opposing processes of ICP4-dependent
repression and ICP0-dependent antirepression appear to dictate whether the
ICP0 gene will remain ON or OFF in HSV-infected cells (Figure 3B).

4.1.3. ICP0 as a regulatory subunit of ICP4: a missing lynchpin in HSV gene
regulation?
The 1298-amino-acid ICP4 protein functions as an essential activator that
recruits cellular TATA-binding protein complexes to HSV genomes, and thus
stimulates mRNA synthesis from HSV E and L genes (88). ICP4 also possesses
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a second activity as a repressor of HSV IE genes, which requires the binding of
350 kDa ICP4 homodimers to consensus ATCGTC sequences (116, 117). To
date, it remains unclear how the balance between ICP4’s opposing
transcriptional repressor versus activator functions is controlled.
Since the discovery that ICP0 re-organizes PML nuclear bodies (30), ICP4
and ICP0 have been predominantly studied in isolation from one another.
However, ICP0 was initially discovered as a factor that stimulated a 20-fold
increase in ICP4-dependent mRNA synthesis from HSV E and L promoters (9).
The results of the current study establish that ICP0 and ICP4 participate in a
robust physical interaction in HSV-infected cells (Figure 9). We postulate that
ICP0’s physical interaction with ICP4 is likely regulatory in nature, and hence
may be relevant in explaining how ICP0 potentiates ICP4-dependent E and L
mRNA synthesis (8, 9), as well as how ICP0 antagonizes ICP4-dependent
repression of ICP0 mRNA synthesis (Figure 3 - 5). Therefore, we propose that
the accumulation of ICP0 in HSV-infected cells (or lack thereof) may dictate
whether ICP4 functions predominantly as an activator, or a repressor, of HSV
mRNA synthesis. Further studies will be required to test the validity of this
important hypothesis.

4.1.4. How does ICP0 antagonize ICP4-dependent repression?
What specific protein-DNA complexes explain how ICP0 antagonizes
ICP4-dependent silencing of the ICP0 gene? The mechanisms that underlie the
phenomenon documented in this study are unknown, and further study will be
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required to differentiate between scores of possibilities. In an effort to illustrate
this point, we present two distinct molecular models that are compatible with the
results of the current study.
The first model, the ICP0-ICP4 Interference Model, is the most intuitively
obvious interpretation and may reflect the mental model that many readers have
invoked up to this point in the manuscript to make sense of the results. Under an
ICP0-ICP4 Interference Model, it could be predicted that 1. ICP4 binding to HSV
dsDNA serves the sole purpose of repressing mRNA synthesis from adjacent
HSV genes, and that 2. ICP0 blocks ICP4’s capacity to bind dsDNA, and thus
ICP0 blocks ICP4-dependent repression of the HSV ICP0 gene. However,
synthesis of ICP4 is required for synthesis of viral E and L mRNAs, and
mutations that disrupt ICP4’s DNA-binding domain also render HSV incapable of
synthesizing its ~70 E and L mRNAs that are required for HSV replication (71,
83, 118). Therefore, it is difficult to envision how an ICP0-based activity that
dislodges ICP4 from dsDNA would help explain how ICP0 potentiates ICP4dependent synthesis of HSV E and L mRNAs (8, 9).
An ICP0-ICP4 Synergy Model is less intuitively obvious, but is more
consistent with ICP0’s capacity to enhance ICP4-dependent synthesis of HSV E
and L mRNAs. Under this latter model, it may be envisioned that 1. the
functional purpose of ICP4 and the >50 ICP4-binding sites that span the HSV
genome is to allow ICP4 to form a histone-like scaffold that coats HSV genomes;
2. the 1298 amino-acid ICP4 protein possesses numerous domains that allow
ICP4 to interact with cellular proteins (119, 120) and viral proteins (Figure 9)
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which influence whether ICP4 stimulates or represses mRNA synthesis from the
underlying HSV DNA; and 3. the nature of ICP0’s interaction with ICP4 relates to
potentiating ICP4-dependent activation of mRNA synthesis from HSV DNA.
Clearly, further investigation will be required to determine if the specific proteinDNA interactions that occur in HSV-infected cells are consistent with an ICP0ICP4 Synergy Model of HSV gene regulation.

4.1.5. Repression-antirepression model of ICP0 gene regulation:
evolutionarily conserved gene regulation scheme?
The herpesviruses and temperate bacteriophage are large dsDNA viruses
that share the capacity to alternate between productive and silent infections.
Many similarities have emerged in the mechanisms that herpesviruses and the
tailed bacteriophage employ to replicate and encapsulate their large dsDNA
genomes (121-124). Such observations point to a common evolutionary
ancestry between these two ancient families of viruses (125, 126). We conclude
that the results of the current study appear to add to this growing list of
inexplicable similarities.
The parallel capacity of HSV and bacteriophage λ to alternate between
productive and silent infections may not be a coincidence. Rather, both viruses
may control the onset of viral replication through a system of repression and
antirepression of a few IE proteins whose accumulation, or lack thereof, dictates
the probability of replication. In λ phage, the ‘decision’ between productive
versus silent infections hinges upon whether the λ cro antirepressor gene is
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expressed or repressed (127-129). Thus, important questions follow from the
observation that HSV encodes its own transcriptional repressor function,
embedded in ICP4, which is capable of silencing the HSV antirepressor gene that
encodes ICP0. Further study will be required to determine if, in fact, repressionantirepression of the ICP0 gene is relevant to the natural process by which HSV
‘decides’ whether a given infection will be productive or silent.

4.2. FUNCTION OF ICP0

4.2.1. ICP0 serves distinct roles in the nucleus and cytoplasm of HSVinfected cells
Studies of ICP0 have focused on the protein’s role in the nucleus (17, 27,
53, 54). Cytoplasmic ICP0 has been repeatedly observed (48-52), but its
significance remains obscure for two reasons. First, the kinetics of ICP0’s
nuclear-to-cytoplasmic translocation has been poorly defined. Thus, it has not
been apparent that ICP0’s function in the cytoplasm is kinetically delayed and is
only manifest once ICP0 fulfills its IE function in the nucleus (8, 9, 39). Second,
the role that ICP0 fulfills in the cytoplasm of HSV-infected cells has not been
clearly articulated. The results of the current study address these gaps in
knowledge.
The results of the current study demonstrate that once E proteins
accumulate, ICP0 translocates to the cytoplasm (Fig. 12) and there dismantles
the host cell’s microtubule network. Five observations support this conclusion: 1.
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Microtubule dispersal is ICP0-dependent in HSV-infected cells (Fig. 16); 2.
Synthesis of ICP0 is sufficient to trigger microtubule dispersal (Fig. 17); 3.
Dispersal of microtubule bundles is dependent upon ICP0’s RING finger domain
(Fig. 14); 4. The timing of microtubule dispersal coincides with ICP0’s
translocation to the cytoplasm (Fig. 16); and 5. α-tubulin+ breakdown products
co-localize with ICP0 (Fig. 16).

4.2.2. GFP-tagged ICP0 yields new insights into the biology of ICP0
HSV-1 viruses that encoded chimeric ICP0+GFP proteins formed plaques
with ~66% efficiency relative to wild-type HSV-1 (Fig. 1E). Using this new tool,
we were able to observe GFP-tagged ICP0 in the act of bundling and/or
dispersing microtubules in the cytoplasm of HSV-infected cells. These findings
would be difficult to ascertain from analysis of fixed cells because ICP0’s
cytoplasmic pattern is pleomorphic in HSV-infected cells. However, direct
observation of a single HSV-infected cell in real time reveals the fluid process by
which GFP-tagged ICP0 triggers the disassembly of subcellular structures, which
proved to be part of the microtubule network (Figs. 13 and 14; Table 3).

4.2.3. Virus-induced reorganization of host cell microtubules
Many animal and plant viruses use host cell microtubule networks during
their replication cycle (59-61). For example, movement protein of tobacco
mosaic virus (130) and transmission factor of cauliflower mosaic virus (131)
modify microtubules in plant cells. The human immunodeficiency virus Rev
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protein forms dimers that bind microtubule ends, and inhibit their polymerization
(132). The 3C protease of foot-and-mouth disease virus cleaves microtubuleassociated protein 4, and thus excludes microtubules from cytoplasmic
replication compartments (58, 133). Expression of Epstein-Barr virus’s LMP-1
protein or SV40’s large T antigen causes formation of aberrant microtubule
structures via the respective modulation of microtubule-stabilizing proteins
RASSF1 A (134) and TACC2 (59). While many viruses modify the microtubule
network during their replication cycles, the functional significance of these
interactions is often unclear. Thus, there is no clear virological precedent that
explains why HSV should encode a protein, ICP0, that dismantles the
microtubule network.

4.2.4. ICP0: a viral E3 ligase that orchestrates microtubule disassembly
The current study provides the first example of a viral E3 ligase that
triggers microtubule disassembly. Most of the ~20 α-herpesviruses whose
genomes have been sequenced encode RING-finger E3 ligases (65). These
include varicella-zoster virus (135), pseudorabies virus (136), and channel catfish
virus (137). Based on our results, we predict that each of these RING-finger E3
ligases will also 1. fulfill dual roles in the nucleus and cytoplasm of virus-infected
cells, and 2. will dismantle microtubule networks upon their translocation to the
cytoplasm. Clearly, further testing is required to test the validity of this prediction.
The α-herpesviruses are not alone in their use of E3 ligases as regulatory
molecules. The Rta protein of Kaposi’s sarcoma herpesvirus possesses intrinsic
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E3 ligase activity despite the absence of a canonical RING finger domain (138).
Intriguingly, both ICP0 and Rta E3 ligases are sufficient to trigger reactivation of
latent herpesviral infections (10, 139). Most viruses are too small to encode their
own E3 ligases. Thus, smaller RNA and DNA viruses exploit ubiquitination as a
regulatory mechanism by encoding adapter proteins such as adenovirus E1b,
papillomavirus E6 and E7, or paramyxovirus V proteins that redirect cellular E3
ligases to substrates that benefit the virus (138, 140-143). It will be of interest to
determine in coming years if any of these other viral E3 ligases reorganize host
cell microtubule networks.
Many cellular E3 ligases play a prominent role in coordinating the complex
events that transpire during mitosis, and which include disassembly of the
microtubule network (63). For example, cullin 3 is an E3 ligase that regulates the
activity of a microtubule-severing protein known as katanin (i.e., ‘sword’ in
Japanese; Ref. (63, 64, 144)). Given the propensity of viruses to steal useful
cellular functions (138, 145), our results raise the possibility that ICP0 may be
derived from one of the many cellular E3 ligases that influences cell-cycle
progression via regulating the disassembly and reassembly of microtubule
networks (63). Specifically, our results imply that ICP0 possesses a mitosisrelated regulatory activity that is manifest upon its translocation to the cytoplasm.
Further investigation will be required to test the validity of this important
hypothesis.
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4.2.5. Is α-tubulin a substrate of ICP0’s E3 ligase activity?
The discovery of ICP0’s E3 ligase activity by Everett and colleagues (15,
16) arose from a need to explain why PML nuclear bodies were dispersed shortly
after ICP0 arrived in these sub-nuclear structures (30, 42, 43). Although it
seemed likely that PML would prove to be a direct substrate of ICP0’s E3 ligase
activity, the development of a robust in vitro assay for ICP0’s E3 ligase activity
demonstrated that this was not the case (15, 45).
It is possible that α-tubulin may be a direct substrate of ICP0’s E3 ligase
activity, but the history of ICP0 research suggests that such speculation is
premature. What should be considered, however, is the extraordinarily robust
co-localization of α-tubulin and ICP0. For example, in transfected cells, large
amounts of α-tubulin co-localized with ICP0 in the nucleus, which is not normally
observed in uninfected cells (Fig. 17). These results suggest that newly
synthesized ICP0 may be tethered to α-tubulin so rapidly in the cytoplasm that
the ICP0-containing complexes that are imported into the nucleus may also
contain sizable amounts of α-tubulin. Moreover, ICP0 co-localized with
dispersed α-tubulin+ structures for hours after disassembly of the microtubule
network (Fig. 14, 16, 17). In contrast, ICP0’s nuclear interactions with PML (30,
43) and ICP4 (39, 80) appear to be far more transient in nature. Clearly, further
work is needed to define how ICP0’s E3 ligase activity triggers microtubule
disassembly in host cells, and to define why ICP0’s interaction with α-tubulin
appears to be so much more stable than any other cellular protein identified to
date.
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4.2.6. ICP0-induced disassembly of microtubules versus G2/M cell cycle
arrest
Synthesis of ICP0 causes dividing cells to arrest in the G2/M phase of the
cell cycle (27, 46, 47). Two explanations for this phenomenon have been offered
including ICP0-induced degradation of centromere protein-C (27), and ICP0induced activation of a DNA damage response pathway (146). The current study
suggests a third possibility; ICP0-induced disassembly of microtubules produces
the same type of G2/M arrest that is caused by nocodazole (147).
The rationale for this proposal is explained. The microtubule bundles in
which ICP0ΔRING stably accumulated (Figs. 13 and 14) were rapidly destabilized
upon treatment with nocodazole (Fig. 15). The resulting ICP0ΔRING+ globular
bodies that were dispersed upon nocodazole treatment were α-tubulin+, and
were indistinguishable in appearance from the ICP0+ α-tubulin+ globular bodies
that formed in HSV-infected cells (Fig. 18). Thus, our results suggest that, like
nocodazole, ICP0 triggers the rapid disassembly of microtubules.
Nocodazole causes cells to arrest in the G2/M phase of the cell cycle by
blocking mitotic spindle formation, which is needed to align chromosomes on the
metaphase plate prior to their segregation into daughter cells (147). Thus,
nocodazole treatment causes cell division to arrest in prometaphase (148).
Likewise, synthesis of ICP0 has nocodazole-like effects on cell division (46, 47).
Specifically, chromosome condensation occurs normally in cells treated with
ICP0-expressing viruses (27) or nocodazole (148), but in both cases the
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condensed chromosomes fail to align on metaphase plates (27, 148). Further
work will be required to test the validity of this interpretation, and determine if
ICP0-induced disassembly of microtubules explains why synthesis of ICP0
causes cell division to stall during mitosis.

4.2.7. Functional consequences of host cell microtubule networks
disruption by herpesviruses
In recent years, the list of viruses that interact with cellular microtubules
has grown in length, but the general significance of the phenomenon remains
unclear. Herpesviruses rely on microtubules as a ‘conveyor belt’ to carry their
incoming virions from the cell membrane to the nuclear pore (103, 149).
Therefore, it is conceivable that disruption of this conveyor belt may be critical for
virion egress, such that newly formed herpesvirus virions may flow efficiently in
the reverse direction, from the nucleus back to the cell membrane. Of course,
many other possibilities exist and warrant equal consideration. For example,
ICP0-induced disruption of microtubules may elicit massive changes in the cell’s
metabolism that may be needed late in infection to produce the vast quantities of
energy and protein required during the logarithmic phase of virion synthesis
(150). Likewise, if microtubule disassembly is linked to ICP0’s capacity to disrupt
mitosis, it is conceivable that microtubule disassembly could provide signals that
would cause the host cell to respond by producing a whole suite of DNA repair
enzymes that might be critical for the synthesis, recombination, and/or packaging
of HSV DNA (54). Whatever the correct explanation proves to be, it should
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account for the fact that modulation of microtubules is not HSV-specific, but
rather is likely critical to the herpesviruses as a group. In light of these
considerations, it will be of particular interest to determine in coming years if viral
E3 ligase-dependent dismantling of microtubule networks is unique to the
herpesviruses, or rather is paralleled in the replication strategies of other plant
and animal viruses (151-153).
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CHAPTER 5: CONCLUSION

Two questions were posed at the beginning of the dissertation: 1) how is
ICP0 gene regulated, and 2) what function does ICP0 assumes. Regarding to
the first question, we found that ICP0 gene is subject to potent ICP4-dependent
repression immediately following HSV infection. ICP0 physically interacts with
ICP4, and antagonizes ICP4’s repressive activity. Therefore, we conclude that
ICP0 gene is differentially regulated by virus-encoded repressor ICP4 and virusencoded antirepressor ICP0. The balance between ICP0 and ICP4 likely
determines the “ON” and “OFF” of ICP0 gene, which contributes to the lytic
versus latent decision of HSV.
Our pursuit of the second question began as we unexpectedly found that
ICP0 is predominantly localized to the cytoplasm of HSV-infected cells. Further
investigations showed that ICP0 translocates from nucleus to cytoplasm during
the early phase of infection, where it bundles and disperses host cell microtubule
networks. The RING-finger domain, which confers E3 ligase activity to ICP0, is
required to the microtubule-dispersing activity, not the microtubule-bundling
activity. Our study represents the first report of a virus-encoded E3 ligase that
disrupts microtubule networks of the host cell. Since nearly all the αherpesviruses encode an E3 ligase, our findings hint a general function of virusencoded E3 ligase, which is to dismantle microtubule networks.
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Finally, we conclude that ICP0 assume dual functions during the life cycle of
HSV: 1) In the very early stage of HSV replication, ICP0 is an exclusively nuclear
protein, which promotes HSV gene expression through antagonizing ICP4’s
repressive activity; 2) In the very late stage of HSV replication, ICP0 translocates
to the cytoplasm, where it dismantles host cell microtubule networks, which may
facilitate viral spread.
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